{"matching_results": 32824, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1084, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 763}, {"key": "negative", "matching_results": 311}, {"key": "neutral", "matching_results": 10}]}]}, {"key": "freelancer.com.co", "matching_results": 686, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 643}, {"key": "negative", "matching_results": 40}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "theolympiareport.com", "matching_results": 656, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 462}, {"key": "negative", "matching_results": 192}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "tickerreport.com", "matching_results": 645, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 555}, {"key": "negative", "matching_results": 90}]}]}, {"key": "thelincolnianonline.com", "matching_results": 624, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 430}, {"key": "negative", "matching_results": 194}]}]}, {"key": "zolmax.com", "matching_results": 621, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 464}, {"key": "negative", "matching_results": 157}]}]}, {"key": "wkrb13.com", "matching_results": 614, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 485}, {"key": "negative", "matching_results": 129}]}]}, {"key": "findmarketresearch.org", "matching_results": 557, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 471}, {"key": "negative", "matching_results": 85}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "watchlistnews.com", "matching_results": 554, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 418}, {"key": "negative", "matching_results": 136}]}]}, {"key": "marketscreener.com", "matching_results": 490, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 339}, {"key": "negative", "matching_results": 150}, {"key": "neutral", "matching_results": 1}]}]}]}], "results": [{"id": "6pNhoYzldrth1TktxJexZn2s8aL-n6fBaNVzLuozgAsR6V1iDkuZXmcRbH_Mnr5N", "result_metadata": {"score": 38.709614}, "author": "Anonymous", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Simpson Thacher", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.5 Billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Debt", "relevance": 0.839899, "dbpedia_resource": "http://dbpedia.org/resource/Debt"}], "categories": [{"score": 0.848714, "label": "/finance/grants, scholarships and financial aid/government grants"}, {"score": 0.810505, "label": "/finance/investing/funds"}, {"score": 0.729664, "label": "/business and industrial/company/merger and acquisition"}], "relations": [{"type": "hasAttribute", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire", "score": 0.628458, "arguments": [{"text": "Purchasers", "location": [35, 45], "entities": [{"type": "Person", "text": "Purchasers"}]}, {"text": "7.5 Billion", "location": [50, 61], "entities": [{"type": "Money", "text": "7.5 Billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire", "score": 0.978919, "arguments": [{"text": "Notes", "location": [108, 113], "entities": [{"type": "Person", "text": "Notes Offering"}]}, {"text": "Offering", "location": [114, 122], "entities": [{"type": "EventCommunication", "text": "Offering"}]}]}, {"type": "agentOf", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire", "score": 0.707032, "arguments": [{"text": "Takeda", "location": [126, 132], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Offering", "location": [114, 122], "entities": [{"type": "EventCommunication", "text": "Offering"}]}]}], "keywords": [{"text": "Simpson Thacher Represents Initial Purchasers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.988238, "count": 1}, {"text": "Senior Notes Offering", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.851189, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563667, "count": 1}, {"text": "Senior Notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.272406, "count": 1}, {"text": "Acquisition of Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.103411, "count": 1}]}, "crawl_date": "2018-11-29T04:09:52Z", "url": "http://www.legal-monitor.com/news/simpson-thacher-represents-initial-purchasers-eu75-billion-senior-notes-offering-and-55", "host": "legal-monitor.com", "text": "Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) of its \u20ac7.5 billion aggregate principal amount of senior notes.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-28T06:40:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Simpson Thacher", "relevance": 0.758844, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Morgan Stanley MUFG Securities Co.", "relevance": 0.565815, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.330246, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.546985, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "S. Takeda", "relevance": 0.513417, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "J.P. Morgan Securities", "relevance": 0.498792, "type": "Company", "disambiguation": {"subtype": [], "name": "J.P. Morgan & Co.", "dbpedia_resource": "http://dbpedia.org/resource/J.P._Morgan_&_Co."}}, {"count": 2, "sentiment": {"score": 0.366497, "label": "positive"}, "text": "Takeda", "relevance": 0.461473, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.276226, "label": "negative"}, "text": "J.P. Morgan Securities LLC", "relevance": 0.411806, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SMBC Nikko Capital Markets Limited", "relevance": 0.405866, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SMBC Nikko Securities America", "relevance": 0.381732, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HSBC Bank plc", "relevance": 0.355412, "type": "Company", "disambiguation": {"subtype": [], "name": "HSBC Bank (Europe)", "dbpedia_resource": "http://dbpedia.org/resource/HSBC_Bank_(Europe)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays Bank PLC", "relevance": 0.341695, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mizuho Securities USA LLC", "relevance": 0.323836, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.330246, "label": "negative"}, "text": "principal", "relevance": 0.298988, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BNP Paribas", "relevance": 0.279781, "type": "Company", "disambiguation": {"subtype": [], "name": "BNP Paribas", "dbpedia_resource": "http://dbpedia.org/resource/BNP_Paribas"}}, {"count": 1, "sentiment": {"score": -0.276226, "label": "negative"}, "text": "Japan", "relevance": 0.252201, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Fenner & Smith Incorporated", "relevance": 0.243417, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.24107, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.419233, "label": "positive"}, "text": "Jennie Getsin", "relevance": 0.23669, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merrill Lynch", "relevance": 0.2313, "type": "Company", "disambiguation": {"subtype": [], "name": "Merrill Lynch", "dbpedia_resource": "http://dbpedia.org/resource/Merrill_Lynch"}}, {"count": 1, "sentiment": {"score": 0.419233, "label": "positive"}, "text": "Sarah Julian Duffy", "relevance": 0.230269, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.317235, "label": "positive"}, "text": "Jonathan Cantor", "relevance": 0.222891, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alan Cannon", "relevance": 0.219014, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.215015, "type": "Organization", "disambiguation": {"subtype": ["Magazine"], "name": "Inc. (magazine)", "dbpedia_resource": "http://dbpedia.org/resource/Inc._(magazine)"}}, {"count": 1, "sentiment": {"score": 0.317235, "label": "positive"}, "text": "Yu Mizutani", "relevance": 0.207954, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.207103, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pierce", "relevance": 0.204182, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Snowden", "relevance": 0.197329, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.5 Billion", "relevance": 0.197329, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.5 billion", "relevance": 0.197329, "type": "Quantity"}], "sentiment": {"document": {"score": 0.75795, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Simpson Thacher", "keywords": [{"text": "Simpson Thacher"}], "entities": [{"type": "Person", "text": "Simpson Thacher"}]}, "sentence": " Simpson Thacher recently represented the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) of its \u20ac7.5 billion aggregate principal amount of senior notes.", "object": {"text": "the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) of its \u20ac7.5 billion aggregate principal amount of senior notes", "keywords": [{"text": "Morgan Securities plc"}, {"text": "Barclays Bank PLC"}, {"text": "HSBC Bank plc"}, {"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "J.P. Morgan Securities", "disambiguation": {"subtype": [], "name": "J.P. Morgan & Co.", "dbpedia_resource": "http://dbpedia.org/resource/J.P._Morgan_&_Co."}}, {"type": "Company", "text": "SMBC Nikko Capital Markets Limited"}, {"type": "Company", "text": "Morgan Stanley MUFG Securities Co."}, {"type": "Company", "text": "Ltd."}, {"type": "Company", "text": "Barclays Bank PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"type": "Company", "text": "BNP Paribas", "disambiguation": {"subtype": ["Company"], "name": "BNP Paribas", "dbpedia_resource": "http://dbpedia.org/resource/BNP_Paribas"}}, {"type": "Company", "text": "HSBC Bank plc", "disambiguation": {"subtype": ["Company"], "name": "HSBC Bank (Europe)", "dbpedia_resource": "http://dbpedia.org/resource/HSBC_Bank_(Europe)"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}, {"type": "JobTitle", "text": "principal"}]}, "action": {"verb": {"text": "represent", "tense": "past"}, "text": "represented", "normalized": "represent"}}, {"subject": {"text": "by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) of its \u20ac7.5 billion aggregate principal amount of senior notes", "keywords": [{"text": "Morgan Securities plc"}, {"text": "Barclays Bank PLC"}, {"text": "HSBC Bank plc"}, {"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "J.P. Morgan Securities", "disambiguation": {"subtype": [], "name": "J.P. Morgan & Co.", "dbpedia_resource": "http://dbpedia.org/resource/J.P._Morgan_&_Co."}}, {"type": "Company", "text": "SMBC Nikko Capital Markets Limited"}, {"type": "Company", "text": "Morgan Stanley MUFG Securities Co."}, {"type": "Company", "text": "Ltd."}, {"type": "Company", "text": "Barclays Bank PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"type": "Company", "text": "BNP Paribas", "disambiguation": {"subtype": ["Company"], "name": "BNP Paribas", "dbpedia_resource": "http://dbpedia.org/resource/BNP_Paribas"}}, {"type": "Company", "text": "HSBC Bank plc", "disambiguation": {"subtype": ["Company"], "name": "HSBC Bank (Europe)", "dbpedia_resource": "http://dbpedia.org/resource/HSBC_Bank_(Europe)"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}, {"type": "JobTitle", "text": "principal"}]}, "sentence": " Simpson Thacher recently represented the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) of its \u20ac7.5 billion aggregate principal amount of senior notes.", "object": {"text": "the initial purchasers", "keywords": [{"text": "initial purchasers"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "The notes", "keywords": [{"text": "notes"}]}, "sentence": " The notes were issued in six series with maturities ranging from 2020 to 2030.Simpson Thacher also represented the initial purchasers, led by J.P. Morgan Securities LLC, SMBC Nikko Securities America, Inc., Morgan Stanley MUFG Securities Co., Ltd., Mizuho Securities USA LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in the offering by Takeda of its $5.5 billion aggregate principal amount of senior notes.", "object": {"text": "issued in six series with maturities", "keywords": [{"text": "maturities"}, {"text": "series"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "six series with maturities ranging from 2020 to 2030.Simpson Thacher", "keywords": [{"text": "2030.Simpson Thacher"}, {"text": "maturities"}, {"text": "series"}], "entities": [{"type": "Person", "text": "Simpson Thacher"}]}, "sentence": " The notes were issued in six series with maturities ranging from 2020 to 2030.Simpson Thacher also represented the initial purchasers, led by J.P. Morgan Securities LLC, SMBC Nikko Securities America, Inc., Morgan Stanley MUFG Securities Co., Ltd., Mizuho Securities USA LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in the offering by Takeda of its $5.5 billion aggregate principal amount of senior notes.", "object": {"text": "the initial purchasers, led by J.P. Morgan Securities LLC, SMBC Nikko Securities America, Inc., Morgan Stanley MUFG Securities Co., Ltd., Mizuho Securities USA LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in the offering by Takeda of its $5.5 billion aggregate principal amount of senior notes", "keywords": [{"text": "J.P. Morgan Securities"}, {"text": "SMBC Nikko Securities"}, {"text": "Mizuho Securities USA"}, {"text": "Stanley MUFG Securities"}], "entities": [{"type": "Company", "text": "J.P. Morgan Securities LLC"}, {"type": "Company", "text": "SMBC Nikko Securities America"}, {"type": "Organization", "text": "Inc.", "disambiguation": {"subtype": ["Magazine"], "name": "Inc. (magazine)", "dbpedia_resource": "http://dbpedia.org/resource/Inc._(magazine)"}}, {"type": "Company", "text": "Morgan Stanley MUFG Securities Co."}, {"type": "Company", "text": "Ltd."}, {"type": "Company", "text": "Mizuho Securities USA LLC"}, {"type": "Company", "text": "Merrill Lynch", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merrill Lynch", "dbpedia_resource": "http://dbpedia.org/resource/Merrill_Lynch"}}, {"type": "Person", "text": "Pierce"}, {"type": "Company", "text": "Fenner & Smith Incorporated"}, {"type": "Company", "text": "Takeda"}, {"type": "JobTitle", "text": "principal"}, {"type": "Quantity", "text": "$5.5 billion"}]}, "action": {"verb": {"text": "represent", "tense": "past"}, "text": "represented", "normalized": "represent"}}, {"subject": {"text": "by J.P. Morgan Securities LLC, SMBC Nikko Securities America, Inc., Morgan Stanley MUFG Securities Co., Ltd., Mizuho Securities USA LLC and Merrill Lynch", "keywords": [{"text": "J.P. Morgan Securities"}, {"text": "SMBC Nikko Securities"}, {"text": "Mizuho Securities"}, {"text": "Securities Co."}], "entities": [{"type": "Company", "text": "J.P. Morgan Securities LLC"}, {"type": "Company", "text": "SMBC Nikko Securities America"}, {"type": "Organization", "text": "Inc.", "disambiguation": {"subtype": ["Magazine"], "name": "Inc. (magazine)", "dbpedia_resource": "http://dbpedia.org/resource/Inc._(magazine)"}}, {"type": "Company", "text": "Morgan Stanley MUFG Securities Co."}, {"type": "Company", "text": "Ltd."}, {"type": "Company", "text": "Mizuho Securities USA LLC"}, {"type": "Company", "text": "Merrill Lynch", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merrill Lynch", "dbpedia_resource": "http://dbpedia.org/resource/Merrill_Lynch"}}]}, "sentence": " The notes were issued in six series with maturities ranging from 2020 to 2030.Simpson Thacher also represented the initial purchasers, led by J.P. Morgan Securities LLC, SMBC Nikko Securities America, Inc., Morgan Stanley MUFG Securities Co., Ltd., Mizuho Securities USA LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in the offering by Takeda of its $5.5 billion aggregate principal amount of senior notes.", "object": {"text": "the initial purchasers", "keywords": [{"text": "initial purchasers"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}], "concepts": [{"text": "Bank of America", "relevance": 0.964735, "dbpedia_resource": "http://dbpedia.org/resource/Bank_of_America"}, {"text": "Primary dealers", "relevance": 0.839294, "dbpedia_resource": "http://dbpedia.org/resource/Primary_dealers"}, {"text": "Merrill Lynch", "relevance": 0.780529, "dbpedia_resource": "http://dbpedia.org/resource/Merrill_Lynch"}, {"text": "Morgan Stanley", "relevance": 0.760697, "dbpedia_resource": "http://dbpedia.org/resource/Morgan_Stanley"}, {"text": "Lehman Brothers", "relevance": 0.736797, "dbpedia_resource": "http://dbpedia.org/resource/Lehman_Brothers"}, {"text": "Investment banks", "relevance": 0.650342, "dbpedia_resource": "http://dbpedia.org/resource/Investment_banks"}, {"text": "Subprime mortgage crisis", "relevance": 0.565562, "dbpedia_resource": "http://dbpedia.org/resource/Subprime_mortgage_crisis"}, {"text": "Global ATM Alliance", "relevance": 0.554641, "dbpedia_resource": "http://dbpedia.org/resource/Global_ATM_Alliance"}, {"text": "Banks based in New York City", "relevance": 0.541451, "dbpedia_resource": "http://dbpedia.org/resource/Banks_based_in_New_York_City"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.506632, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Barclays", "relevance": 0.505589, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "BNP Paribas", "relevance": 0.504793, "dbpedia_resource": "http://dbpedia.org/resource/BNP_Paribas"}, {"text": "Barclays Bank plc", "relevance": 0.500321, "dbpedia_resource": "http://dbpedia.org/resource/Barclays_Bank_plc"}, {"text": "Premier League", "relevance": 0.498427, "dbpedia_resource": "http://dbpedia.org/resource/Premier_League"}, {"text": "Debt", "relevance": 0.488833, "dbpedia_resource": "http://dbpedia.org/resource/Debt"}, {"text": "HSBC", "relevance": 0.475117, "dbpedia_resource": "http://dbpedia.org/resource/HSBC"}, {"text": "FTSE 100 Index", "relevance": 0.470599, "dbpedia_resource": "http://dbpedia.org/resource/FTSE_100_Index"}, {"text": "Mitsubishi UFJ Financial Group", "relevance": 0.470314, "dbpedia_resource": "http://dbpedia.org/resource/Mitsubishi_UFJ_Financial_Group"}, {"text": "Securities Act of 1933", "relevance": 0.464466, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Act_of_1933"}, {"text": "Banks of the United Kingdom", "relevance": 0.451274, "dbpedia_resource": "http://dbpedia.org/resource/Banks_of_the_United_Kingdom"}, {"text": "Marcus Agius", "relevance": 0.445783, "dbpedia_resource": "http://dbpedia.org/resource/Marcus_Agius"}, {"text": "Finance", "relevance": 0.439017, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "United Kingdom", "relevance": 0.430988, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}], "categories": [{"score": 0.91547, "label": "/finance/bank"}, {"score": 0.845525, "label": "/finance/investing"}, {"score": 0.845525, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire 28 Nov 2018 Simpson Thacher recently represented the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\"Takeda\") of its \u20a07.5 billion aggregate principal amount of senior notes.", "score": 0.447779, "arguments": [{"text": "Simpson Thacher", "location": [0, 15], "entities": [{"type": "Person", "text": "Simpson Thacher"}]}, {"text": "7.5 Billion", "location": [50, 61], "entities": [{"type": "Money", "text": "7.5 Billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "The notes were issued in four series with maturities ranging from 2020 to 2028.The notes in each offering were sold to international investors outside of Japan in reliance on Rule 144A and Regulation S. Takeda intends to use the net proceeds from the offerings to fund a portion of the cash consideration to be paid in connection with its acquisition of Shire plc.", "score": 0.325734, "arguments": [{"text": "Shire plc", "location": [1312, 1321], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "acquisition", "location": [1297, 1308], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "Takeda is a global, research and development-driven pharmaceutical company with a presence in more than 70 countries.", "score": 0.236819, "arguments": [{"text": "pharmaceutical company", "location": [1374, 1396], "entities": [{"type": "Organization", "text": "pharmaceutical company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda", "location": [1322, 1328], "entities": [{"type": "Organization", "text": "Takeda"}]}]}, {"type": "locatedAt", "sentence": "Takeda is a global, research and development-driven pharmaceutical company with a presence in more than 70 countries.", "score": 0.70826, "arguments": [{"text": "pharmaceutical company", "location": [1374, 1396], "entities": [{"type": "Organization", "text": "pharmaceutical company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "countries", "location": [1429, 1438], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "managerOf", "sentence": "The Simpson Thacher team for the offerings included Alan Cannon, David Snowden and Yu Mizutani (Capital Markets); Jonathan Cantor and Sarah Julian Duffy (Tax); and Jennie Getsin (Blue Sky).", "score": 0.535435, "arguments": [{"text": "Simpson Thacher", "location": [1443, 1458], "entities": [{"type": "Person", "text": "Simpson Thacher"}]}, {"text": "team", "location": [1459, 1463], "entities": [{"type": "Organization", "text": "team", "disambiguation": {"subtype": ["Sports"]}}]}]}, {"type": "employedBy", "sentence": "The Simpson Thacher team for the offerings included Alan Cannon, David Snowden and Yu Mizutani (Capital Markets); Jonathan Cantor and Sarah Julian Duffy (Tax); and Jennie Getsin (Blue Sky).", "score": 0.721715, "arguments": [{"text": "Yu Mizutani", "location": [1522, 1533], "entities": [{"type": "Person", "text": "Yu Mizutani"}]}, {"text": "Capital Markets", "location": [1535, 1550], "entities": [{"type": "Organization", "text": "Capital Markets", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The Simpson Thacher team for the offerings included Alan Cannon, David Snowden and Yu Mizutani (Capital Markets); Jonathan Cantor and Sarah Julian Duffy (Tax); and Jennie Getsin (Blue Sky).", "score": 0.568196, "arguments": [{"text": "Sarah Julian Duffy", "location": [1573, 1591], "entities": [{"type": "Person", "text": "Sarah Julian Duffy"}]}, {"text": "Tax", "location": [1593, 1596], "entities": [{"type": "Organization", "text": "Tax", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The Simpson Thacher team for the offerings included Alan Cannon, David Snowden and Yu Mizutani (Capital Markets); Jonathan Cantor and Sarah Julian Duffy (Tax); and Jennie Getsin (Blue Sky).", "score": 0.77361, "arguments": [{"text": "Jennie Getsin", "location": [1603, 1616], "entities": [{"type": "Person", "text": "Jennie Getsin"}]}, {"text": "Blue Sky", "location": [1618, 1626], "entities": [{"type": "Organization", "text": "Blue Sky", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Matter Type Banking & Finance - Capital Markets: Debt Industry", "score": 0.408152, "arguments": [{"text": "Capital Markets", "location": [1661, 1676], "entities": [{"type": "Organization", "text": "Capital Markets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Matter Type Banking & Finance", "location": [1629, 1658], "entities": [{"type": "Organization", "text": "Matter Type Banking & Finance", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire 28 Nov 2018 Simpson Thacher recently represented the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\"Takeda\") of its \u20a07.5 billion aggregate principal amount of senior notes.", "score": 0.451393, "arguments": [{"text": "Simpson Thacher", "location": [0, 15], "entities": [{"type": "Person", "text": "Simpson Thacher"}]}, {"text": "Offering", "location": [114, 122], "entities": [{"type": "EventCommunication", "text": "Offering"}]}]}, {"type": "hasAttribute", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire 28 Nov 2018 Simpson Thacher recently represented the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\"Takeda\") of its \u20a07.5 billion aggregate principal amount of senior notes.", "score": 0.50073, "arguments": [{"text": "Purchasers", "location": [35, 45], "entities": [{"type": "Person", "text": "Purchasers"}]}, {"text": "7.5 Billion", "location": [50, 61], "entities": [{"type": "Money", "text": "7.5 Billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire 28 Nov 2018 Simpson Thacher recently represented the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\"Takeda\") of its \u20a07.5 billion aggregate principal amount of senior notes.", "score": 0.88794, "arguments": [{"text": "Notes", "location": [108, 113], "entities": [{"type": "Person", "text": "Notes Offering"}]}, {"text": "Offering", "location": [114, 122], "entities": [{"type": "EventCommunication", "text": "Offering"}]}]}, {"type": "hasAttribute", "sentence": "Simpson Thacher Represents Initial Purchasers in \u20a07.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire 28 Nov 2018 Simpson Thacher recently represented the initial purchasers, led by J.P. Morgan Securities plc, SMBC Nikko Capital Markets Limited, Morgan Stanley MUFG Securities Co., Ltd., Barclays Bank PLC, BNP Paribas and HSBC Bank plc, in the offering by Takeda Pharmaceutical Company Limited (\"Takeda\") of its \u20a07.5 billion aggregate principal amount of senior notes.", "score": 0.823585, "arguments": [{"text": "its", "location": [476, 479], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "7.5 billion", "location": [481, 492], "entities": [{"type": "Money", "text": "7.5 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOf", "sentence": "The notes were issued in six series with maturities ranging from 2020 to 2030.Simpson Thacher also represented the initial purchasers, led by J.P. Morgan Securities LLC, SMBC Nikko Securities America, Inc., Morgan Stanley MUFG Securities Co., Ltd., Mizuho Securities USA LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in the offering by Takeda of its $5.5 billion aggregate principal amount of senior notes.", "score": 0.450023, "arguments": [{"text": "Takeda", "location": [887, 893], "entities": [{"type": "Organization", "text": "Takeda"}]}, {"text": "its", "location": [897, 900], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "The notes were issued in six series with maturities ranging from 2020 to 2030.Simpson Thacher also represented the initial purchasers, led by J.P. Morgan Securities LLC, SMBC Nikko Securities America, Inc., Morgan Stanley MUFG Securities Co., Ltd., Mizuho Securities USA LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in the offering by Takeda of its $5.5 billion aggregate principal amount of senior notes.", "score": 0.647972, "arguments": [{"text": "its", "location": [897, 900], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$5.5 billion", "location": [901, 913], "entities": [{"type": "Money", "text": "$5.5 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "residesIn", "sentence": "The notes were issued in four series with maturities ranging from 2020 to 2028.The notes in each offering were sold to international investors outside of Japan in reliance on Rule 144A and Regulation S. Takeda intends to use the net proceeds from the offerings to fund a portion of the cash consideration to be paid in connection with its acquisition of Shire plc.", "score": 0.345107, "arguments": [{"text": "investors", "location": [1091, 1100], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Japan", "location": [1112, 1117], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "The notes were issued in four series with maturities ranging from 2020 to 2028.The notes in each offering were sold to international investors outside of Japan in reliance on Rule 144A and Regulation S. Takeda intends to use the net proceeds from the offerings to fund a portion of the cash consideration to be paid in connection with its acquisition of Shire plc.", "score": 0.71151, "arguments": [{"text": "its", "location": [1293, 1296], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1297, 1308], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Senior Notes Offering", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.82944, "count": 1}, {"text": "J.P. Morgan Securities plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.737552, "count": 1}, {"text": "Simpson Thacher Represents Initial Purchasers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.731753, "count": 1}, {"text": "Simpson Thacher", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625984, "count": 2}, {"text": "Morgan Stanley MUFG Securities Co.", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.625832, "count": 2}, {"text": "Senior Notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620245, "count": 1}, {"text": "SMBC Nikko Capital Markets Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595296, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590928, "count": 1}, {"text": "pharmaceutical company", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.58704, "count": 1}, {"text": "HSBC Bank plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585045, "count": 1}, {"text": "international investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583048, "count": 1}, {"text": "principal amount of senior notes", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.582265, "count": 2}, {"text": "Merrill Lynch", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.574045, "count": 1}, {"text": "BNP Paribas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569548, "count": 1}, {"text": "Capital Markets", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.557824, "count": 2}, {"text": "J.P. Morgan Securities LLC", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.555503, "count": 1}, {"text": "Barclays Bank PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552788, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.75795, "label": "positive"}, "relevance": 0.546248, "count": 4}, {"text": "series", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526407, "count": 2}, {"text": "notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519156, "count": 3}, {"text": "Ltd", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.518376, "count": 2}, {"text": "Mizuho Securities USA LLC", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.516203, "count": 1}, {"text": "presence", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.515133, "count": 1}, {"text": "development", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.513703, "count": 1}, {"text": "SMBC Nikko Securities America", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.513444, "count": 1}, {"text": "research", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.5134, "count": 1}, {"text": "countries", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.513206, "count": 1}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511559, "count": 1}, {"text": "reliance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511394, "count": 1}, {"text": "offerings", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.509952, "count": 2}, {"text": "Fenner", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.509627, "count": 1}, {"text": "Matter Type Banking", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50887, "count": 1}, {"text": "Finance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508731, "count": 1}, {"text": "Regulation S. Takeda", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.508694, "count": 1}, {"text": "connection", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.508287, "count": 1}, {"text": "Tax", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.504977, "count": 1}, {"text": "Acquisition of Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50444, "count": 1}, {"text": "initial purchasers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503518, "count": 2}, {"text": "Simpson Thacher team", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.502034, "count": 1}, {"text": "portion of the cash consideration", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.497659, "count": 1}, {"text": "Rule 144A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496196, "count": 1}, {"text": "net proceeds", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.492231, "count": 1}, {"text": "Alan Cannon", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.486008, "count": 1}, {"text": "Smith Incorporated", "sentiment": {"score": 0.608472, "label": "positive"}, "relevance": 0.485468, "count": 1}, {"text": "acquisition of Shire plc", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.480174, "count": 1}, {"text": "David Snowden", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.478617, "count": 1}, {"text": "Yu Mizutani", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.475985, "count": 1}, {"text": "Sarah Julian Duffy", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.473507, "count": 1}, {"text": "Jonathan Cantor", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.473403, "count": 1}, {"text": "Jennie Getsin", "sentiment": {"score": 0.871409, "label": "positive"}, "relevance": 0.447041, "count": 1}]}, "extracted_metadata": {"sha1": "0f81b77c8a748f2cadcdc464d35a0eab9e0ca546", "filename": "1543464592555.zip-01adfd8c8fe454fb5838fe28ea237a71.xml", "file_type": "json"}, "external_links": ["http://xmlns.com/foaf/0.1/", "http://purl.org/rss/1.0/modules/content/", "http://purl.org/dc/terms/", "http://rdfs.org/sioc/types#", "http://rdfs.org/sioc/ns#"], "title": "Simpson Thacher Represents Initial Purchasers in \u20ac7.5 Billion Senior Notes Offering and $5.5 Billion Senior Notes Offering by Takeda to Finance its Acquisition of Shire", "forum_title": "Legal Monitor"}, {"id": "NfqnwGV-afGwbQPiNAyP7jEPU-Wl9sIhUHTBJvOPTa1AZ5Rrw4ohCae1loIhLsMy", "result_metadata": {"score": 36.035492}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Stock market", "relevance": 0.928193, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "London Stock Exchange", "relevance": 0.81081, "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}, {"text": "Stock exchange", "relevance": 0.767321, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "London", "relevance": 0.5355, "dbpedia_resource": "http://dbpedia.org/resource/London"}, {"text": "Stock", "relevance": 0.518143, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}], "categories": [{"score": 0.861029, "label": "/finance/investing"}, {"score": 0.861029, "label": "/finance/investing/beginning investing"}, {"score": 0.832083, "label": "/finance/investing/day trading"}], "relations": [], "keywords": [{"text": "London Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999792, "count": 1}, {"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.746312, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601989, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412759, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.043456, "count": 1}]}, "crawl_date": "2018-11-29T14:57:38Z", "url": "https://www.marketscreener.com/LONDON-STOCK-EXCHANGE-4005918/news/London-Stock-Exchange-HBK-Investments-LP-Form-8-3-Takeda-Pharmaceutical-Co-Ltd-27681375/", "host": "marketscreener.com", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.614424, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.554792, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.532546, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.525182, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jonathan Brown", "relevance": 0.508787, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501383, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.49134, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.473142, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.473142, "type": "Quantity"}], "sentiment": {"document": {"score": 0.570084, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Takeda Pharmaceutical Co Ltd (d)", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "state the latest practicable date prior to the disclosure 28 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "latest practicable date"}, {"text": "disclosure"}, {"text": "addition"}, {"text": "state"}]}, "sentence": " For an opening position disclosure, state the latest practicable date prior to the disclosure 28 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " 1.369 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "1.369 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " 1.369 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "the Code", "keywords": [{"text": "Code"}]}, "sentence": " Date of disclosure: 29 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.957224, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.517898, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Futures contract", "relevance": 0.50988, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Strike price", "relevance": 0.499479, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.490819, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.448664, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.419005, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.409351, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.403402, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Security", "relevance": 0.384182, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Derivative", "relevance": 0.376662, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Unit type", "relevance": 0.37247, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Stock", "relevance": 0.370859, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option contract", "relevance": 0.361642, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Short", "relevance": 0.35803, "dbpedia_resource": "http://dbpedia.org/resource/Short_(finance)"}, {"text": "Derivatives", "relevance": 0.348958, "dbpedia_resource": "http://dbpedia.org/resource/Derivatives"}, {"text": "Security", "relevance": 0.345676, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.343438, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.339372, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Moneyness", "relevance": 0.338731, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Long", "relevance": 0.337732, "dbpedia_resource": "http://dbpedia.org/resource/Long_(finance)"}], "categories": [{"score": 0.939586, "label": "/real estate/buying and selling homes"}, {"score": 0.870436, "label": "/finance/financial news"}, {"score": 0.805223, "label": "/finance/investing/funds"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [311, 316], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [289, 292], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Ordinary (ISIN: JP3463 4) Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 100 0.000 0 0.000 (2) Cash-settled derivatives: 10,739,200 1.369 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:  TOTAL: 100 0.000 10,739,200 1.369 All interests and all short positions should be disclosed.", "score": 0.531913, "arguments": [{"text": "Number % Number %", "location": [1682, 1699], "entities": [{"type": "Organization", "text": "Number % Number %", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Interests Short", "location": [1656, 1671], "entities": [{"type": "Organization", "text": "Interests Short", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit Ordinary Total Return Swap Increasing a short position 213,600 USD 36.8780 Ordinary Total Return Swap Increasing a short position 700,000 USD 37.0109 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.726237, "arguments": [{"text": "i", "location": [3347, 3348], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3350, 3357], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3947, 3952], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3957, 3961], "entities": [{"type": "Organization", "text": "Price per unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4321, 4327], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4338, 4345], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 29 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [5228, 5234], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5242, 5246], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5309, 5333], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5301, 5306], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5588, 5612], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5580, 5585], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5644, 5649], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5663, 5690], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.795107, "count": 5}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.694448, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.661139, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.643813, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612218, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.607343, "count": 3}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595302, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.592787, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.570873, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563695, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559289, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.554779, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.545892, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.54534, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542909, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.540531, "count": 2}, {"text": "Jonathan Brown Telephone number", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.53797, "count": 1}, {"text": "unit Ordinary Total Return Swap", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537711, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532239, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.531499, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.531146, "count": 1}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.529604, "count": 1}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.527874, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.527749, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525076, "count": 1}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.524831, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524726, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.522633, "count": 2}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.522412, "count": 1}, {"text": "sale Number of securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522031, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.521448, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.519105, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518406, "count": 1}, {"text": "options", "sentiment": {"score": 0.688082, "label": "positive"}, "relevance": 0.516615, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.516583, "count": 2}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.516307, "count": 6}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.515088, "count": 1}, {"text": "subscription", "sentiment": {"score": 0.684266, "label": "positive"}, "relevance": 0.514296, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.514202, "count": 4}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.514069, "count": 3}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51373, "count": 1}, {"text": "unit", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.51362, "count": 4}, {"text": "relation", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.513073, "count": 3}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512439, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511977, "count": 1}, {"text": "November", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.511773, "count": 2}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.510902, "count": 2}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.509951, "count": 3}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509899, "count": 1}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.509634, "count": 1}]}, "extracted_metadata": {"sha1": "f6180a3dc2920c7557e33fe50fa86188048b8cd7", "filename": "1543503458316.zip-3beb48f58f7130142ee714958531fdf6.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "London Stock Exchange : HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "9vuDbDyi7TgFgTNUCGe7WXsdnA7W76J4fd17KV72hn8rx6Id-hJLkK2qaJG0xqVm", "result_metadata": {"score": 36.012375}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Stock market", "relevance": 0.928193, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "London Stock Exchange", "relevance": 0.81081, "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}, {"text": "Stock exchange", "relevance": 0.767321, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "London", "relevance": 0.5355, "dbpedia_resource": "http://dbpedia.org/resource/London"}, {"text": "Stock", "relevance": 0.518143, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}], "categories": [{"score": 0.861029, "label": "/finance/investing"}, {"score": 0.861029, "label": "/finance/investing/beginning investing"}, {"score": 0.832083, "label": "/finance/investing/day trading"}], "relations": [], "keywords": [{"text": "London Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999883, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.603694, "count": 1}, {"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581571, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.189586, "count": 1}]}, "crawl_date": "2018-11-29T14:35:20Z", "url": "http://www.4-traders.com/LONDON-STOCK-EXCHANGE-4005918/news/London-Stock-Exchange-HBK-Investments-LP-Form-8-3-Takeda-Pharmaceutical-Co-Ltd-27681375/", "host": "4-traders.com", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T00:00:00+01:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.614424, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.554792, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.532546, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.525182, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jonathan Brown", "relevance": 0.508787, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501383, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.49134, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.473142, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.473142, "type": "Quantity"}], "sentiment": {"document": {"score": 0.570084, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Takeda Pharmaceutical Co Ltd (d)", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "state the latest practicable date prior to the disclosure 28 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "latest practicable date"}, {"text": "disclosure"}, {"text": "addition"}, {"text": "state"}]}, "sentence": " For an opening position disclosure, state the latest practicable date prior to the disclosure 28 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " 1.369 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "1.369 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " 1.369 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "the Code", "keywords": [{"text": "Code"}]}, "sentence": " Date of disclosure: 29 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.957224, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.517898, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Futures contract", "relevance": 0.50988, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Strike price", "relevance": 0.499479, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.490819, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.448664, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.419005, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.409351, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.403402, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Security", "relevance": 0.384182, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Derivative", "relevance": 0.376662, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Unit type", "relevance": 0.37247, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Stock", "relevance": 0.370859, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option contract", "relevance": 0.361642, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Short", "relevance": 0.35803, "dbpedia_resource": "http://dbpedia.org/resource/Short_(finance)"}, {"text": "Derivatives", "relevance": 0.348958, "dbpedia_resource": "http://dbpedia.org/resource/Derivatives"}, {"text": "Security", "relevance": 0.345676, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.343438, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.339372, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Moneyness", "relevance": 0.338731, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Long", "relevance": 0.337732, "dbpedia_resource": "http://dbpedia.org/resource/Long_(finance)"}], "categories": [{"score": 0.939586, "label": "/real estate/buying and selling homes"}, {"score": 0.870436, "label": "/finance/financial news"}, {"score": 0.805223, "label": "/finance/investing/funds"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [311, 316], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [289, 292], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Ordinary (ISIN: JP3463 4) Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 100 0.000 0 0.000 (2) Cash-settled derivatives: 10,739,200 1.369 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:  TOTAL: 100 0.000 10,739,200 1.369 All interests and all short positions should be disclosed.", "score": 0.531913, "arguments": [{"text": "Number % Number %", "location": [1682, 1699], "entities": [{"type": "Organization", "text": "Number % Number %", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Interests Short", "location": [1656, 1671], "entities": [{"type": "Organization", "text": "Interests Short", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit Ordinary Total Return Swap Increasing a short position 213,600 USD 36.8780 Ordinary Total Return Swap Increasing a short position 700,000 USD 37.0109 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.726237, "arguments": [{"text": "i", "location": [3347, 3348], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3350, 3357], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3947, 3952], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3957, 3961], "entities": [{"type": "Organization", "text": "Price per unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4321, 4327], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4338, 4345], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 29 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [5228, 5234], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5242, 5246], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5309, 5333], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5301, 5306], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5588, 5612], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5580, 5585], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5644, 5649], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5663, 5690], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.795107, "count": 5}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.694448, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.661139, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.643813, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612218, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.607343, "count": 3}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595302, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.592787, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.570873, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563695, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559289, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.554779, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.545892, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.54534, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542909, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.540531, "count": 2}, {"text": "Jonathan Brown Telephone number", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.53797, "count": 1}, {"text": "unit Ordinary Total Return Swap", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537711, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532239, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.531499, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.531146, "count": 1}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.529604, "count": 1}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.527874, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.527749, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525076, "count": 1}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.524831, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524726, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.522633, "count": 2}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.522412, "count": 1}, {"text": "sale Number of securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522031, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.521448, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.519105, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518406, "count": 1}, {"text": "options", "sentiment": {"score": 0.688082, "label": "positive"}, "relevance": 0.516615, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.516583, "count": 2}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.516307, "count": 6}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.515088, "count": 1}, {"text": "subscription", "sentiment": {"score": 0.684266, "label": "positive"}, "relevance": 0.514296, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.514202, "count": 4}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.514069, "count": 3}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51373, "count": 1}, {"text": "unit", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.51362, "count": 4}, {"text": "relation", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.513073, "count": 3}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512439, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511977, "count": 1}, {"text": "November", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.511773, "count": 2}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.510902, "count": 2}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.509951, "count": 3}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509899, "count": 1}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.509634, "count": 1}]}, "extracted_metadata": {"sha1": "ecd1e4811b89b844505d7285dee3f04212034826", "filename": "1543502120222.zip-c62586230b5ad1b13c568e10722591e8.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "London Stock Exchange : HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "Markets : News, Companies, All News - Marketscreener.com"}, {"id": "cgbAKhw3bgbE2CTiG7-WYOyst05KnyOPev1oFM59R_ijITOBuLKQLILoFoa-lxHa", "result_metadata": {"score": 35.225254}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Barclays", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.828046, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.623728, "label": "/law, govt and politics/government"}, {"score": 0.617218, "label": "/business and industrial/shipbuilding"}], "relations": [{"type": "partOf", "sentence": "BARCLAYS PLC Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT | Business Wire", "score": 0.370083, "arguments": [{"text": "Business Wire", "location": [67, 80], "entities": [{"type": "Organization", "text": "Business Wire", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT", "location": [24, 64], "entities": [{"type": "Organization", "text": "TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "PLC Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.922557, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.866376, "count": 1}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581345, "count": 1}, {"text": "Business Wire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.18844, "count": 1}]}, "crawl_date": "2018-11-29T10:32:28Z", "url": "https://www.businesswire.com/news/home/20181129005244/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T08:02:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADR Purchase", "relevance": 0.820312, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.71839, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.686438, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.571374, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": -0.284957, "label": "negative"}, "text": "Class of Product Nature", "relevance": 0.560655, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.558333, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.546471, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.519163, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.477261, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.466751, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.450807, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,374,000 1.31%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,542,474 1.47%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,020,186 1.64%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,250,505 1.67%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,566,105 4.35%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "35,084,260 4.43%", "relevance": 0.450807, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.450807, "type": "Quantity"}], "sentiment": {"document": {"score": 0.637805, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 35,084,260 4.43% 34,566,105 4.35% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "34,566,105 4.35"}, {"type": "Quantity", "text": "35,084,260 4.43"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,542,474 1.47% 13,250,505 1.67% (2) Cash-settled derivatives: 13,020,186 1.64% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 35,084,260 4.43% 34,566,105 4.35% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "35,084,260 4.43% 34,566,105 4.35% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "34,566,105 4.35"}, {"type": "Quantity", "text": "35,084,260 4.43"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,542,474 1.47% 13,250,505 1.67% (2) Cash-settled derivatives: 13,020,186 1.64% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 35,084,260 4.43% 34,566,105 4.35% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 29 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.956834, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.749594, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.682783, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.595033, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.565458, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.415819, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.405059, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Options", "relevance": 0.375731, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.373059, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "United States dollar", "relevance": 0.34434, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Security", "relevance": 0.341904, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.319583, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.317946, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.317765, "dbpedia_resource": "http://dbpedia.org/resource/December"}], "categories": [{"score": 0.85835, "label": "/real estate/buying and selling homes"}, {"score": 0.802473, "label": "/finance/financial news"}, {"score": 0.786315, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 27 4,318.5681 JPY Ordinary NPV SWAP Long 75 4,301.4031 JPY Ordinary NPV SWAP Long 226 4,299.0700 JPY Ordinary NPV SWAP Long 771 4,307.5325 JPY Ordinary NPV SWAP Long 1,152 4,308.7490 JPY Ordinary NPV SWAP Long 2,485 4,303.8764 JPY Ordinary NPV SWAP Long 3,112 4,303.4695 JPY Ordinary NPV SWAP Long 7,582 4,305.3187 JPY Ordinary NPV SWAP Long 11,703 4,310.0527 JPY Ordinary NPV SWAP Long 12,267 4,304.2273 JPY Ordinary NPV SWAP Short 700 4,288.5714 JPY Ordinary NPV SWAP Short 8,200 4,286.6907 JPY Ordinary NPV CFD Short 48,100 4,288.0000 JPY Ordinary NPV SWAP Short 48,100 4,288.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing,", "score": 0.682599, "arguments": [{"text": "i", "location": [6108, 6109], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [6111, 6118], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7082, 7088], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7099, 7106], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 29 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [8008, 8014], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [8022, 8026], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [8454, 8460], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8468, 8481], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8089, 8113], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8081, 8086], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10600, 10624], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10592, 10597], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8248, 8253], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8267, 8294], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10759, 10764], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10778, 10805], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8530, 8536], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8562, 8574], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.743306, "count": 6}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.666686, "count": 13}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.641916, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.63949, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.627114, "count": 2}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.605838, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.587352, "count": 5}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.578753, "count": 3}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.576647, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.576376, "count": 2}, {"text": "relevant Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.57446, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571535, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.570767, "count": 2}, {"text": "Takeover Code", "sentiment": {"score": 0.492251, "mixed": "1", "label": "positive"}, "relevance": 0.569653, "count": 2}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.543931, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.541745, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540841, "count": 2}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533837, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.533684, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.532139, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531574, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.530895, "count": 8}, {"text": "Ordinary NPV Interests Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530233, "count": 1}, {"text": "JPY Ordinary NPV SWAP Long", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.528209, "count": 9}, {"text": "options", "sentiment": {"score": 0.769049, "label": "positive"}, "relevance": 0.527721, "count": 5}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526398, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.525963, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.525509, "count": 1}, {"text": "sale Number of Price", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.523393, "count": 1}, {"text": "Class of Product Nature", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.522222, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.521749, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.521406, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519626, "count": 1}, {"text": "Expiry date Option money", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.518445, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.517957, "count": 2}, {"text": "employee options", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.516032, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.515577, "count": 3}, {"text": "PERSON", "sentiment": {"score": 0.44419, "mixed": "1", "label": "positive"}, "relevance": 0.515116, "count": 7}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.514052, "count": 5}, {"text": "identity of offeror", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.513124, "count": 1}, {"text": "controller of interest", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.512556, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.512434, "count": 2}, {"text": "Supplemental Form", "sentiment": {"score": 0.708155, "label": "positive"}, "relevance": 0.511894, "count": 4}, {"text": "Sales", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.511682, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.51148, "count": 1}, {"text": "relation", "sentiment": {"score": 0.664279, "label": "positive"}, "relevance": 0.511386, "count": 5}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.510673, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510099, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.881961, "label": "negative"}, "relevance": 0.509981, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.509979, "count": 2}]}, "extracted_metadata": {"sha1": "2bec71086c83aa5e91ec788d2afc06ebce5abcfb", "filename": "1543487548590.zip-fc2de3d4212e36f1c2eb9b71e6e9198a.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk"], "title": "BARCLAYS PLC Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT | Business Wire", "forum_title": "All News | Business Wire"}, {"id": "hncm6Ov7zUNkxHCCwRSfJnXIG1PdOEO-wZGLCnzMxILMcV29DD83qJpdzwPPY06R", "result_metadata": {"score": 33.943962}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.325017, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.900486, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.986463, "count": 1}, {"text": "Barclays", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.861851, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.739127, "count": 1}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592004, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.1607, "count": 1}]}, "crawl_date": "2018-11-29T08:59:20Z", "url": "https://www.marketscreener.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-AMENDMENT-27678198/", "host": "marketscreener.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.75369, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADR Purchase", "relevance": 0.747076, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.64309, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.598663, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.53391, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": -0.284957, "label": "negative"}, "text": "Class of Product Nature", "relevance": 0.512191, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.435505, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.426393, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.410886, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,374,000 1.31%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,542,474 1.47%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,020,186 1.64%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,250,505 1.67%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,566,105 4.35%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "35,084,260 4.43%", "relevance": 0.410886, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.410886, "type": "Quantity"}], "sentiment": {"document": {"score": 0.612886, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 35,084,260 4.43% 34,566,105 4.35% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "34,566,105 4.35"}, {"type": "Quantity", "text": "35,084,260 4.43"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,542,474 1.47% 13,250,505 1.67% (2) Cash-settled derivatives: 13,020,186 1.64% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 35,084,260 4.43% 34,566,105 4.35% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "35,084,260 4.43% 34,566,105 4.35% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "34,566,105 4.35"}, {"type": "Quantity", "text": "35,084,260 4.43"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,542,474 1.47% 13,250,505 1.67% (2) Cash-settled derivatives: 13,020,186 1.64% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 35,084,260 4.43% 34,566,105 4.35% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 29 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 29 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 29 November 2018 08:16:09 UTC", "object": {"text": "09 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.971931, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.762003, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.695367, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.604022, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.575535, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.425393, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.409295, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Options", "relevance": 0.379584, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.379501, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "United States dollar", "relevance": 0.35344, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Security", "relevance": 0.348313, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Barclays", "relevance": 0.335647, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Contract", "relevance": 0.324963, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "December", "relevance": 0.32404, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Bond", "relevance": 0.323755, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}], "categories": [{"score": 0.857503, "label": "/real estate/buying and selling homes"}, {"score": 0.803828, "label": "/finance/financial news"}, {"score": 0.783575, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 27 4,318.5681 JPY Ordinary NPV SWAP Long 75 4,301.4031 JPY Ordinary NPV SWAP Long 226 4,299.0700 JPY Ordinary NPV SWAP Long 771 4,307.5325 JPY Ordinary NPV SWAP Long 1,152 4,308.7490 JPY Ordinary NPV SWAP Long 2,485 4,303.8764 JPY Ordinary NPV SWAP Long 3,112 4,303.4695 JPY Ordinary NPV SWAP Long 7,582 4,305.3187 JPY Ordinary NPV SWAP Long 11,703 4,310.0527 JPY Ordinary NPV SWAP Long 12,267 4,304.2273 JPY Ordinary NPV SWAP Short 700 4,288.5714 JPY Ordinary NPV SWAP Short 8,200 4,286.6907 JPY Ordinary NPV CFD Short 48,100 4,288.0000 JPY Ordinary NPV SWAP Short 48,100 4,288.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing,", "score": 0.682599, "arguments": [{"text": "i", "location": [6106, 6107], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [6109, 6116], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7080, 7086], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7097, 7104], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 29 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [8006, 8012], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [8020, 8024], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [8452, 8458], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8466, 8479], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8087, 8111], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8079, 8084], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10598, 10622], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10590, 10595], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8246, 8251], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8265, 8292], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10757, 10762], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10776, 10803], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8528, 8534], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8560, 8572], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181129005244/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 29 November 2018 and is solely responsible for the information contained herein.", "score": 0.979718, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10969, 11002], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [11003, 11012], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181129005244/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 29 November 2018 and is solely responsible for the information contained herein.", "score": 0.735356, "arguments": [{"text": "November 2018", "location": [11032, 11045], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [11003, 11012], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.738215, "count": 6}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.658719, "count": 13}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.642541, "count": 1}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.635324, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.625264, "count": 2}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.604413, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.584745, "count": 5}, {"text": "Takeover Code", "sentiment": {"score": 0.492251, "mixed": "1", "label": "positive"}, "relevance": 0.581754, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.574831, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.573872, "count": 2}, {"text": "relevant Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.572012, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.56965, "count": 2}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.569129, "count": 3}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564674, "count": 1}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.546171, "count": 1}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543839, "count": 2}, {"text": "Purchases", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.540349, "count": 1}, {"text": "View source version", "sentiment": {"score": -0.481928, "label": "negative"}, "relevance": 0.537281, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.535645, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53409, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.533359, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531035, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.529816, "count": 8}, {"text": "Ordinary NPV Interests Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528315, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527385, "count": 1}, {"text": "options", "sentiment": {"score": 0.769049, "label": "positive"}, "relevance": 0.526868, "count": 5}, {"text": "JPY Ordinary NPV SWAP Long", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.526325, "count": 9}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.525758, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.525154, "count": 1}, {"text": "Class of Product Nature", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.522647, "count": 1}, {"text": "sale Number of Price", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.522541, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.521617, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.52116, "count": 1}, {"text": "Expiry date Option money", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.520086, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.517645, "count": 2}, {"text": "employee options", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.515618, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.44419, "mixed": "1", "label": "positive"}, "relevance": 0.515121, "count": 7}, {"text": "INTERESTS", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.51502, "count": 3}, {"text": "identity of offeror", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.514237, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.513686, "count": 5}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.512118, "count": 2}, {"text": "controller of interest", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.51194, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.511636, "count": 1}, {"text": "Supplemental Form", "sentiment": {"score": 0.708155, "label": "positive"}, "relevance": 0.511596, "count": 4}, {"text": "relation", "sentiment": {"score": 0.659149, "label": "positive"}, "relevance": 0.511527, "count": 5}, {"text": "Sales", "sentiment": {"score": -0.389405, "label": "negative"}, "relevance": 0.51142, "count": 1}, {"text": "Code", "sentiment": {"score": -0.375081, "mixed": "1", "label": "negative"}, "relevance": 0.511016, "count": 5}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.510572, "count": 1}, {"text": "Details", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.50972, "count": 2}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509444, "count": 1}]}, "extracted_metadata": {"sha1": "4ce09f68d2406b572503a8e19de5b813d0344f48", "filename": "1543481960059.zip-b6a739f02c4e3a918154551108f4d068.xml", "file_type": "json"}, "external_links": ["http://www.publicnow.com/view/EE50148894454ABA87D8D713AAEE4E93AD047467", "http://www.thetakeoverpanel.org.uk", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1212873", "https://www.businesswire.com/news/home/20181129005244/en/"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "dmRu1pZk9eXDgGG_DZeaIXYbdJNyUsQB0ex0H-9BY3K8FpBVOK8-zNFI5MopCxOl", "result_metadata": {"score": 32.636635}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.607673, "label": "/finance/investing/brokerages"}, {"score": 0.605701, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.597169, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.752509, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.603694, "count": 1}, {"text": "Daiwa Asset Management UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518959, "count": 1}]}, "crawl_date": "2018-11-29T13:56:24Z", "url": "https://www.businesswire.com/news/home/20181128005900/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T07:00:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.730141, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.64188, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.62331, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.568326, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.546224, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.529882, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.502271, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.498024, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.49128, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.49128, "type": "Quantity"}], "sentiment": {"document": {"score": 0.465235, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "28 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 28 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 660153 Time of Receipt (offset from UTC): 20181129T041937+0000 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.985104, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.521885, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Call option", "relevance": 0.520638, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.502769, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.464876, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.422446, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.413773, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.406606, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.390016, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.386495, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Balance sheet", "relevance": 0.383128, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.379977, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.374884, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.36137, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uniform Commercial Code", "relevance": 0.358362, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.355314, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}], "categories": [{"score": 0.923256, "label": "/real estate/buying and selling homes"}, {"score": 0.835727, "label": "/finance/financial news"}, {"score": 0.706287, "label": "/finance/investing/day trading"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 660153 Time of Receipt (offset from UTC): 20181129T041937+0000 Contacts Daiwa Asset Management", "score": 0.434823, "arguments": [{"text": "UTC", "location": [5847, 5850], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [5826, 5833], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 28 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [700, 707], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [626, 663], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORD Sale 2,500 4156.342 JPY ORD Sale 2,500 4156.342 JPY ORD Sale 5,000 4156.342 JPY ORD Purchase 18,000 4180 JPY ORD Sale 8,700 4180 JPY (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit - - - - - (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.787954, "arguments": [{"text": "i", "location": [3328, 3329], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3331, 3338], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) - - - - 4.", "score": 0.591687, "arguments": [{"text": "Price", "location": [3954, 3959], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3964, 3968], "entities": [{"type": "Organization", "text": "ORD Sale"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4336, 4342], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4353, 4360], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 29 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5172, 5184], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5186, 5215], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 29 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5275, 5281], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5289, 5293], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5356, 5380], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5348, 5353], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5635, 5659], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5627, 5632], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5691, 5696], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5710, 5737], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.756063, "count": 5}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.689008, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.626214, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613057, "count": 1}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610897, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.584963, "count": 3}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581105, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.571977, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.571657, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568388, "count": 1}, {"text": "unit ORD Sale", "sentiment": {"score": 0.719885, "label": "positive"}, "relevance": 0.564903, "count": 1}, {"text": "Telephone number", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.563141, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.562496, "count": 1}, {"text": "sale Number of securities Price", "sentiment": {"score": 0.719885, "label": "positive"}, "relevance": 0.554196, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.54566, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.544327, "count": 1}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.544015, "count": 1}, {"text": "JPY ORD Sale", "sentiment": {"score": 0.719885, "label": "positive"}, "relevance": 0.539932, "count": 3}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534074, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534053, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532845, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.532027, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.530978, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530351, "count": 1}, {"text": "Daiwa Asset Management Co. Ltd", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.530349, "count": 1}, {"text": "cash offer", "sentiment": {"score": -0.5347, "label": "negative"}, "relevance": 0.529731, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529079, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.54238, "label": "positive"}, "relevance": 0.529073, "count": 6}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.528811, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.527197, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.525121, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.524816, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.523328, "count": 1}, {"text": "nature of the rights", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.520917, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520526, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.52039, "count": 2}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.519172, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.518549, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.518089, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.516643, "count": 3}, {"text": "November", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.516428, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.516143, "count": 2}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.516095, "count": 3}, {"text": "options", "sentiment": {"score": 0.343063, "mixed": "1", "label": "positive"}, "relevance": 0.515741, "count": 4}, {"text": "Owner", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.515342, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514336, "count": 1}, {"text": "offer", "sentiment": {"score": 0.618287, "mixed": "1", "label": "positive"}, "relevance": 0.512944, "count": 3}, {"text": "Purchases", "sentiment": {"score": 0.719885, "label": "positive"}, "relevance": 0.511155, "count": 1}, {"text": "Expiry date Option money", "sentiment": {"score": 0.699268, "label": "positive"}, "relevance": 0.511117, "count": 1}, {"text": "Number of securities Exercise price", "sentiment": {"score": 0.699268, "label": "positive"}, "relevance": 0.51093, "count": 1}]}, "extracted_metadata": {"sha1": "69cc235dcc282129553879716104d0507cd71540", "filename": "1543499784518.zip-c3de9ac675f3cde7c23680aee0f69d37.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk"], "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}, {"id": "soWmSAhwP_F8e6pgxtkyBf8XcHLJKEXmtHy9AnUXEQ1TTU7org-4Awcv8xuSoXfo", "result_metadata": {"score": 31.742641}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda rewards Australian medical research grants", "object": {"text": "Australian medical research grants", "keywords": [{"text": "medical research grants"}]}, "action": {"verb": {"text": "reward", "tense": "present"}, "text": "rewards", "normalized": "reward"}}], "concepts": [{"text": "Research", "relevance": 0.9044, "dbpedia_resource": "http://dbpedia.org/resource/Research"}], "categories": [{"score": 0.999965, "label": "/science/medicine/medical research"}, {"score": 0.98859, "label": "/finance/grants, scholarships and financial aid"}], "relations": [], "keywords": [{"text": "Australian medical research grants", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.900278, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.899735, "count": 1}]}, "crawl_date": "2018-11-28T23:38:06Z", "url": "https://www.austrade.gov.au/international/invest/investor-updates/2018/takeda-rewards-australian-medical-research-grants", "host": "austrade.gov.au", "text": "Headquartered in Tokyo, Japan, Takeda Pharmaceuticals was founded in 1781.", "main_image_url": "https://www.austrade.gov.au/images/UserUploadedImages/2791/web-card-investor-update.png", "country": "AU", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-28T04:25:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.809888, "type": "Person"}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Federation University Australia", "relevance": 0.733576, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Managing Director of Takeda Australia", "relevance": 0.67168, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Australia", "relevance": 0.634634, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals", "relevance": 0.531528, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.483267, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 2, "sentiment": {"score": 0.503693, "label": "positive"}, "text": "Australia", "relevance": 0.451559, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Australia", "dbpedia_resource": "http://dbpedia.org/resource/Australia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of South Australia", "relevance": 0.448328, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of South Australia", "dbpedia_resource": "http://dbpedia.org/resource/University_of_South_Australia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shonan Research Centre", "relevance": 0.377326, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Westmead Institute for Medical Research", "relevance": 0.366455, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Research Director", "relevance": 0.348062, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr Mayuresh Korgaonkar", "relevance": 0.332729, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hunter Medical Research Institute", "relevance": 0.330874, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Business Environment and Innovation", "relevance": 0.305195, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr Nikki Verrills", "relevance": 0.286778, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Professor Richard D\u2019Andrea", "relevance": 0.280677, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James Jones", "relevance": 0.276986, "type": "Person", "disambiguation": {"subtype": [], "name": "James Phillips Jones", "dbpedia_resource": "http://dbpedia.org/resource/James_Phillips_Jones"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Queensland", "relevance": 0.27567, "type": "Organization", "disambiguation": {"subtype": ["University"], "name": "University of Queensland", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Queensland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Sydney", "relevance": 0.275292, "type": "Organization", "disambiguation": {"subtype": ["Location", "AcademicInstitution", "CollegeUniversity", "University"], "name": "University of Sydney", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Sydney"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.271946, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Associate Professor", "relevance": 0.27139, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Trent Woodruff", "relevance": 0.270173, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Andrew Greenhill", "relevance": 0.265621, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Newcastle", "relevance": 0.264471, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biotech Dispatch", "relevance": 0.259636, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Lecturer", "relevance": 0.256686, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "School of Biomedical Sciences", "relevance": 0.243524, "type": "Organization"}], "sentiment": {"document": {"score": 0.85317, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "sentence": " Takeda , Japan\u2019s largest pharmaceutical company, has awarded individual grants of approximately A$100,000 to four Australian research programs as part of its COCKPI-T open innovation program.", "object": {"text": "largest pharmaceutical company", "keywords": [{"text": "largest pharmaceutical company"}], "entities": []}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Takeda , Japan\u2019s largest pharmaceutical company,", "keywords": [{"text": "largest pharmaceutical company"}, {"text": "Takeda"}, {"text": "Japan"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "sentence": " Takeda , Japan\u2019s largest pharmaceutical company, has awarded individual grants of approximately A$100,000 to four Australian research programs as part of its COCKPI-T open innovation program.", "object": {"text": "individual grants of approximately A$100,000", "keywords": [{"text": "individual grants"}, {"text": "100,000"}]}, "action": {"verb": {"text": "award", "tense": "past"}, "text": "has awarded", "normalized": "have award"}}, {"subject": {"text": "The program", "keywords": [{"text": "program"}]}, "sentence": " The program is designed to support Australian research projects with the aim of advancing therapeutic targets and technologies in drug discovery.", "object": {"text": "Australian research projects", "keywords": [{"text": "Australian research projects"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "is designed to support", "normalized": "be design to support"}}, {"subject": {"text": "It"}, "sentence": " It funds early-stage research proposals related to therapeutic targets and technologies for drug discovery in neuroscience, oncology, gastroenterology and regenerative medicine.", "object": {"text": "early-stage research proposals related to therapeutic targets and technologies for drug discovery in neuroscience, oncology, gastroenterology and regenerative medicine", "keywords": [{"text": "early-stage research proposals"}, {"text": "therapeutic targets"}, {"text": "regenerative medicine"}, {"text": "drug discovery"}]}, "action": {"verb": {"text": "fund", "tense": "present"}, "text": "funds", "normalized": "fund"}}, {"subject": {"text": "the candidates, who were selected from more than 60 applicants,", "keywords": [{"text": "candidates"}, {"text": "applicants"}]}, "sentence": " As well as receiving individual grants, the candidates, who were selected from more than 60 applicants, are eligible for in-kind support from Takeda personnel.", "object": {"text": "eligible for in-kind support from Takeda personnel", "keywords": [{"text": "in-kind support"}, {"text": "Takeda personnel"}, {"text": "eligible"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "\u2018Takeda", "keywords": [{"text": "\u2018Takeda"}]}, "sentence": " \u2018Takeda is pleased to be able to support and encourage high-quality Australian research through investment in these early-stage programs at various universities,\u2019 says James Jones, Managing Director of Takeda Australia in Biotech Dispatch .", "object": {"text": "high-quality Australian research", "keywords": [{"text": "high-quality Australian research"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "\u2018Takeda", "keywords": [{"text": "\u2018Takeda"}]}, "sentence": " \u2018Takeda is pleased to be able to support and encourage high-quality Australian research through investment in these early-stage programs at various universities,\u2019 says James Jones, Managing Director of Takeda Australia in Biotech Dispatch .", "object": {"text": "high-quality Australian research", "keywords": [{"text": "high-quality Australian research"}]}, "action": {"verb": {"text": "encourage", "tense": "present"}, "text": "encourage", "normalized": "encourage"}}, {"subject": {"text": "\u2018The COCKPI-T Australia 2018 program", "keywords": [{"text": "COCKPI-T Australia"}, {"text": "program"}], "entities": [{"type": "Location", "text": "Australia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Australia", "dbpedia_resource": "http://dbpedia.org/resource/Australia"}}]}, "sentence": " \u2018The COCKPI-T Australia 2018 program attracted many excellent applications across the therapeutic areas that Takeda focuses on, reaffirming Australia\u2019s strong reputation in innovative academic and clinical research.", "object": {"text": "many excellent applications across the therapeutic areas that Takeda focuses on", "keywords": [{"text": "excellent applications"}, {"text": "therapeutic areas"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "attract", "tense": "past"}, "text": "attracted", "normalized": "attract"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " \u2018The COCKPI-T Australia 2018 program attracted many excellent applications across the therapeutic areas that Takeda focuses on, reaffirming Australia\u2019s strong reputation in innovative academic and clinical research.", "object": {"text": "Australia\u2019s strong reputation in innovative academic and clinical research", "keywords": [{"text": "strong reputation"}, {"text": "clinical research"}, {"text": "Australia"}], "entities": [{"type": "Location", "text": "Australia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Australia", "dbpedia_resource": "http://dbpedia.org/resource/Australia"}}]}, "action": {"verb": {"text": "reaffirm", "tense": "present"}, "text": "reaffirming", "normalized": "reaffirm"}}, {"subject": {"text": "\u2018We", "keywords": [{"text": "\u2018We"}]}, "sentence": " \u2018We congratulate the successful applicants and look forward to their contribution in understanding complex disease areas.\u2019", "object": {"text": "the successful applicants", "keywords": [{"text": "successful applicants"}]}, "action": {"verb": {"text": "congratulate", "tense": "present"}, "text": "congratulate", "normalized": "congratulate"}}, {"subject": {"text": "Headquartered in Tokyo, Japan, Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "Tokyo"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Headquartered in Tokyo, Japan, Takeda Pharmaceuticals was founded in 1781.", "object": {"text": "founded in 1781"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceuticals", "keywords": [{"text": "Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Headquartered in Tokyo, Japan, Takeda Pharmaceuticals was founded in 1781.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "Co Create Knowledge for Pharma Innovation with Takeda (COCKPI-T)", "keywords": [{"text": "Pharma Innovation"}, {"text": "Takeda"}, {"text": "Create Knowledge"}, {"text": "COCKPI-T"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Co Create Knowledge for Pharma Innovation with Takeda (COCKPI-T) was launched in Japan in 2015 and introduced to Australia in 2018 \u2013 the first overseas market to receive it.", "object": {"text": "launched in Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Co Create Knowledge for Pharma Innovation with Takeda (COCKPI-T)", "keywords": [{"text": "Pharma Innovation"}, {"text": "Takeda"}, {"text": "Create Knowledge"}, {"text": "COCKPI-T"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Co Create Knowledge for Pharma Innovation with Takeda (COCKPI-T) was launched in Japan in 2015 and introduced to Australia in 2018 \u2013 the first overseas market to receive it.", "action": {"verb": {"text": "launch", "tense": "past"}, "text": "was launched", "normalized": "be launch"}}, {"subject": {"text": "Pharma Innovation with Takeda (COCKPI-T)", "keywords": [{"text": "Pharma Innovation"}, {"text": "Takeda"}, {"text": "COCKPI-T"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Co Create Knowledge for Pharma Innovation with Takeda (COCKPI-T) was launched in Japan in 2015 and introduced to Australia in 2018 \u2013 the first overseas market to receive it.", "object": {"text": "to Australia", "keywords": [{"text": "Australia"}], "entities": [{"type": "Location", "text": "Federation University Australia", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "introduce", "tense": "past"}, "text": "introduced", "normalized": "introduce"}}, {"subject": {"text": "the first overseas market", "keywords": [{"text": "overseas market"}]}, "sentence": " Co Create Knowledge for Pharma Innovation with Takeda (COCKPI-T) was launched in Japan in 2015 and introduced to Australia in 2018 \u2013 the first overseas market to receive it.", "object": {"text": "it"}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "to receive", "normalized": "to receive"}}, {"subject": {"text": "by the company\u2019s Shonan Research Centre", "keywords": [{"text": "Shonan Research Centre"}, {"text": "company"}], "entities": [{"type": "Facility", "text": "Shonan Research Centre"}]}, "sentence": " COCKPI-T in Australia is operated by the company\u2019s Shonan Research Centre in Japan in collaboration with Takeda Australia .", "object": {"text": "COCKPI-T in Australia", "keywords": [{"text": "COCKPI-T"}, {"text": "Australia"}], "entities": [{"type": "Location", "text": "Federation University Australia", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "operate", "tense": "past"}, "text": "is operated", "normalized": "be operate"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " COCKPI-T in Australia is operated by the company\u2019s Shonan Research Centre in Japan in collaboration with Takeda Australia .", "object": {"text": "Shonan Research Centre in Japan", "keywords": [{"text": "Shonan Research Centre"}], "entities": [{"type": "Facility", "text": "Shonan Research Centre"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Australia", "entities": [{"type": "Location", "text": "Federation University Australia", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Compare Australia across key investment indicators \u2013 Economy, Industries, Skilled Labour, Business Environment and Innovation.", "object": {"text": "across key investment indicators \u2013 Economy, Industries, Skilled Labour, Business Environment and Innovation", "keywords": [{"text": "key investment indicators"}, {"text": "Business Environment"}, {"text": "Labour"}, {"text": "Economy"}], "entities": [{"type": "JobTitle", "text": "Business Environment and Innovation"}]}, "action": {"verb": {"text": "Compare", "tense": "present"}, "text": "Compare", "normalized": "Compare"}}], "concepts": [{"text": "Medicine", "relevance": 0.959782, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Professor", "relevance": 0.730429, "dbpedia_resource": "http://dbpedia.org/resource/Professor"}, {"text": "New South Wales", "relevance": 0.610596, "dbpedia_resource": "http://dbpedia.org/resource/New_South_Wales"}, {"text": "Pharmacology", "relevance": 0.601022, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Lecturer", "relevance": 0.587398, "dbpedia_resource": "http://dbpedia.org/resource/Lecturer"}, {"text": "University", "relevance": 0.581705, "dbpedia_resource": "http://dbpedia.org/resource/University"}, {"text": "Australia", "relevance": 0.570485, "dbpedia_resource": "http://dbpedia.org/resource/Australia"}, {"text": "Research and development", "relevance": 0.552695, "dbpedia_resource": "http://dbpedia.org/resource/Research_and_development"}, {"text": "Innovation", "relevance": 0.545059, "dbpedia_resource": "http://dbpedia.org/resource/Innovation"}, {"text": "Queensland", "relevance": 0.490755, "dbpedia_resource": "http://dbpedia.org/resource/Queensland"}, {"text": "Clinical trial", "relevance": 0.429569, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Public university", "relevance": 0.403503, "dbpedia_resource": "http://dbpedia.org/resource/Public_university"}, {"text": "Medical research", "relevance": 0.397576, "dbpedia_resource": "http://dbpedia.org/resource/Medical_research"}, {"text": "Biomedical scientist", "relevance": 0.393688, "dbpedia_resource": "http://dbpedia.org/resource/Biomedical_scientist"}, {"text": "Clinical research", "relevance": 0.392934, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Pharmaceutical industry", "relevance": 0.389931, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pharmaceutical drug", "relevance": 0.378453, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Japan", "relevance": 0.370249, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.356, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pacific Ocean", "relevance": 0.351538, "dbpedia_resource": "http://dbpedia.org/resource/Pacific_Ocean"}, {"text": "Brisbane", "relevance": 0.349738, "dbpedia_resource": "http://dbpedia.org/resource/Brisbane"}, {"text": "South Australia", "relevance": 0.340643, "dbpedia_resource": "http://dbpedia.org/resource/South_Australia"}, {"text": "Sydney", "relevance": 0.337588, "dbpedia_resource": "http://dbpedia.org/resource/Sydney"}], "categories": [{"score": 0.988396, "label": "/science/medicine/medical research"}], "relations": [{"type": "timeOf", "sentence": "RSS Feeds 29 Nov 2018 Takeda , Japan's largest pharmaceutical company, has awarded individual grants of approximately A$100,000 to four Australian research programs as part of its COCKPI-T open innovation program.", "score": 0.516826, "arguments": [{"text": "Feeds\n29 Nov 2018", "location": [4, 21], "entities": [{"type": "Date", "text": "Feeds\n29 Nov 2018"}]}, {"text": "awarded", "location": [75, 82], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "locatedAt", "sentence": "\u02bbTakeda is pleased to be able to support and encourage high-quality Australian research through investment in these early-stage programs at various universities,' says James Jones, Managing Director of Takeda Australia in Biotech Dispatch .", "score": 0.922293, "arguments": [{"text": "Australia", "location": [1430, 1439], "entities": [{"type": "GeopoliticalEntity", "text": "Australian", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Biotech Dispatch", "location": [1443, 1459], "entities": [{"type": "GeopoliticalEntity", "text": "Biotech Dispatch"}]}]}, {"type": "locatedAt", "sentence": "\u02bbThe COCKPI-T Australia 2018 program attracted many excellent applications across the therapeutic areas that Takeda focuses on, reaffirming Australia's strong reputation in innovative academic and clinical research.", "score": 0.402966, "arguments": [{"text": "Takeda", "location": [1571, 1577], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "areas", "location": [1560, 1565], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "locatedAt", "sentence": "' Headquartered in Tokyo, Japan, Takeda Pharmaceuticals was founded in 1781.", "score": 0.942536, "arguments": [{"text": "Tokyo", "location": [1818, 1823], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [1825, 1830], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "' Headquartered in Tokyo, Japan, Takeda Pharmaceuticals was founded in 1781.", "score": 0.306228, "arguments": [{"text": "Takeda Pharmaceuticals", "location": [1832, 1854], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "Tokyo", "location": [1818, 1823], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "COCKPI-T in Australia is operated by the company's Shonan Research Centre in Japan in collaboration with Takeda Australia .", "score": 0.549994, "arguments": [{"text": "COCKPI-T", "location": [2050, 2058], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "Australia", "location": [2062, 2071], "entities": [{"type": "GeopoliticalEntity", "text": "Australian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "COCKPI-T in Australia is operated by the company's Shonan Research Centre in Japan in collaboration with Takeda Australia .", "score": 0.895243, "arguments": [{"text": "Shonan Research Centre", "location": [2101, 2123], "entities": [{"type": "Organization", "text": "Shonan Research Centre"}]}, {"text": "company", "location": [2091, 2098], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}]}, {"type": "locatedAt", "sentence": "COCKPI-T in Australia is operated by the company's Shonan Research Centre in Japan in collaboration with Takeda Australia .", "score": 0.730672, "arguments": [{"text": "Shonan Research Centre", "location": [2101, 2123], "entities": [{"type": "Organization", "text": "Shonan Research Centre"}]}, {"text": "Japan", "location": [2127, 2132], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "COCKPI-T in Australia is operated by the company's Shonan Research Centre in Japan in collaboration with Takeda Australia .", "score": 0.786125, "arguments": [{"text": "Takeda", "location": [2155, 2161], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "Australia", "location": [2162, 2171], "entities": [{"type": "GeopoliticalEntity", "text": "Australian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "RSS Feeds 29 Nov 2018 Takeda , Japan's largest pharmaceutical company, has awarded individual grants of approximately A$100,000 to four Australian research programs as part of its COCKPI-T open innovation program.", "score": 0.460045, "arguments": [{"text": "Takeda", "location": [22, 28], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "awarded", "location": [75, 82], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "basedIn", "sentence": "RSS Feeds 29 Nov 2018 Takeda , Japan's largest pharmaceutical company, has awarded individual grants of approximately A$100,000 to four Australian research programs as part of its COCKPI-T open innovation program.", "score": 0.861372, "arguments": [{"text": "pharmaceutical company", "location": [47, 69], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}, {"text": "Japan", "location": [31, 36], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "RSS Feeds 29 Nov 2018 Takeda , Japan's largest pharmaceutical company, has awarded individual grants of approximately A$100,000 to four Australian research programs as part of its COCKPI-T open innovation program.", "score": 0.483056, "arguments": [{"text": "pharmaceutical company", "location": [47, 69], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}, {"text": "awarded", "location": [75, 82], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "educatedAt", "sentence": "The successful 2018 candidates are: Dr Mayuresh Korgaonkar, Research Director, Westmead Institute for Medical Research and University of Sydney, for neuroscience Associate Professor Trent Woodruff, School of Biomedical Sciences, University of Queensland, for neuro-immunology Andrew Greenhill, Senior Lecturer, Federation University Australia, for gastroenterology Professor Richard D'Andrea, University of South Australia; and Dr Nikki Verrills, University of Newcastle and Hunter Medical Research Institute, for oncology As well as receiving individual grants, the candidates, who were selected from more than 60 applicants, are eligible for in-kind support from Takeda personnel.", "score": 0.491222, "arguments": [{"text": "Trent Woodruff", "location": [720, 734], "entities": [{"type": "Person", "text": "Trent Woodruff"}]}, {"text": "School of Biomedical Sciences", "location": [736, 765], "entities": [{"type": "Organization", "text": "School of Biomedical Sciences", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "partOfMany", "sentence": "The successful 2018 candidates are: Dr Mayuresh Korgaonkar, Research Director, Westmead Institute for Medical Research and University of Sydney, for neuroscience Associate Professor Trent Woodruff, School of Biomedical Sciences, University of Queensland, for neuro-immunology Andrew Greenhill, Senior Lecturer, Federation University Australia, for gastroenterology Professor Richard D'Andrea, University of South Australia; and Dr Nikki Verrills, University of Newcastle and Hunter Medical Research Institute, for oncology As well as receiving individual grants, the candidates, who were selected from more than 60 applicants, are eligible for in-kind support from Takeda personnel.", "score": 0.68064, "arguments": [{"text": "who", "location": [1117, 1120], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "applicants", "location": [1153, 1163], "entities": [{"type": "Person", "text": "applicants"}]}]}, {"type": "agentOf", "sentence": "\u02bbTakeda is pleased to be able to support and encourage high-quality Australian research through investment in these early-stage programs at various universities,' says James Jones, Managing Director of Takeda Australia in Biotech Dispatch .", "score": 0.915186, "arguments": [{"text": "James Jones", "location": [1389, 1400], "entities": [{"type": "Person", "text": "James Jones"}]}, {"text": "says", "location": [1384, 1388], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "locatedAt", "sentence": "\u02bbTakeda is pleased to be able to support and encourage high-quality Australian research through investment in these early-stage programs at various universities,' says James Jones, Managing Director of Takeda Australia in Biotech Dispatch .", "score": 0.476503, "arguments": [{"text": "Managing Director", "location": [1402, 1419], "entities": [{"type": "Person", "text": "James Jones"}]}, {"text": "Australia", "location": [1430, 1439], "entities": [{"type": "GeopoliticalEntity", "text": "Australian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "\u02bbTakeda is pleased to be able to support and encourage high-quality Australian research through investment in these early-stage programs at various universities,' says James Jones, Managing Director of Takeda Australia in Biotech Dispatch .", "score": 0.513617, "arguments": [{"text": "Takeda", "location": [1423, 1429], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "Australia", "location": [1430, 1439], "entities": [{"type": "GeopoliticalEntity", "text": "Australian", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Australian research programs", "sentiment": {"score": 0.743673, "label": "positive"}, "relevance": 0.741056, "count": 1}, {"text": "Federation University Australia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.693776, "count": 1}, {"text": "University of Sydney", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646213, "count": 1}, {"text": "COCKPI-T", "sentiment": {"score": 0.743673, "label": "positive"}, "relevance": 0.644036, "count": 3}, {"text": "Japan\u2019s largest pharmaceutical company", "sentiment": {"score": 0.743673, "label": "positive"}, "relevance": 0.63793, "count": 1}, {"text": "successful applicants", "sentiment": {"score": 0.970056, "label": "positive"}, "relevance": 0.590483, "count": 1}, {"text": "individual grants", "sentiment": {"score": 0.743673, "label": "positive"}, "relevance": 0.586608, "count": 2}, {"text": "Research Director", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58372, "count": 1}, {"text": "University of South Australia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577857, "count": 1}, {"text": "Medical Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573709, "count": 1}, {"text": "Co Create Knowledge", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573131, "count": 1}, {"text": "Australian research projects", "sentiment": {"score": 0.697156, "label": "positive"}, "relevance": 0.572597, "count": 1}, {"text": "Takeda personnel", "sentiment": {"score": 0.996344, "label": "positive"}, "relevance": 0.569257, "count": 1}, {"text": "neuroscience Associate Professor Trent Woodruff", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559691, "count": 1}, {"text": "James Jones", "sentiment": {"score": 0.996344, "label": "positive"}, "relevance": 0.559305, "count": 1}, {"text": "COCKPI-T Australia", "sentiment": {"score": 0.737544, "label": "positive"}, "relevance": 0.557348, "count": 1}, {"text": "various universities", "sentiment": {"score": 0.996344, "label": "positive"}, "relevance": 0.557024, "count": 1}, {"text": "Senior Lecturer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556835, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.845416, "label": "positive"}, "relevance": 0.55519, "count": 4}, {"text": "University of Queensland", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548595, "count": 1}, {"text": "open innovation program", "sentiment": {"score": 0.743673, "label": "positive"}, "relevance": 0.548146, "count": 1}, {"text": "Director of Takeda Australia", "sentiment": {"score": 0.996344, "label": "positive"}, "relevance": 0.545416, "count": 1}, {"text": "stage research proposals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544177, "count": 1}, {"text": "drug discovery", "sentiment": {"score": 0.697156, "label": "positive"}, "relevance": 0.541552, "count": 2}, {"text": "clinical research", "sentiment": {"score": 0.866778, "label": "positive"}, "relevance": 0.535559, "count": 1}, {"text": "Skilled Labour", "sentiment": {"score": 0.880302, "label": "positive"}, "relevance": 0.535357, "count": 1}, {"text": "kind support", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524681, "count": 1}, {"text": "Business Environment", "sentiment": {"score": 0.880302, "label": "positive"}, "relevance": 0.52407, "count": 1}, {"text": "gastroenterology Professor Richard D\u2019Andrea", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523651, "count": 1}, {"text": "neuro-immunology Andrew Greenhill", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522405, "count": 1}, {"text": "candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518412, "count": 2}, {"text": "Dr Mayuresh Korgaonkar", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5184, "count": 1}, {"text": "company\u2019s Shonan Research Centre", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517179, "count": 1}, {"text": "regenerative medicine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516276, "count": 1}, {"text": "investment", "sentiment": {"score": 0.996344, "label": "positive"}, "relevance": 0.51566, "count": 1}, {"text": "School of Biomedical Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515355, "count": 1}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515318, "count": 3}, {"text": "high-quality Australian research", "sentiment": {"score": 0.996344, "label": "positive"}, "relevance": 0.514262, "count": 1}, {"text": "applicants", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51312, "count": 1}, {"text": "neuroscience", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51299, "count": 1}, {"text": "program", "sentiment": {"score": 0.717622, "label": "positive"}, "relevance": 0.512099, "count": 2}, {"text": "gastroenterology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51061, "count": 1}, {"text": "part", "sentiment": {"score": 0.743673, "label": "positive"}, "relevance": 0.510068, "count": 1}, {"text": "Australia", "sentiment": {"score": 0.880302, "label": "positive"}, "relevance": 0.508704, "count": 4}, {"text": "therapeutic targets", "sentiment": {"score": 0.697156, "label": "positive"}, "relevance": 0.507651, "count": 2}, {"text": "Tokyo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507461, "count": 1}, {"text": "early-stage programs", "sentiment": {"score": 0.996344, "label": "positive"}, "relevance": 0.50699, "count": 1}, {"text": "technologies", "sentiment": {"score": 0.697156, "label": "positive"}, "relevance": 0.506395, "count": 2}, {"text": "Economy", "sentiment": {"score": 0.880302, "label": "positive"}, "relevance": 0.506178, "count": 1}, {"text": "Industries", "sentiment": {"score": 0.880302, "label": "positive"}, "relevance": 0.505632, "count": 1}]}, "extracted_metadata": {"sha1": "afcefa08722545258059b2c5d6705fbf039c5002", "filename": "1543448286181.zip-af18fe33eedc0c5d32ffa540ec423fc4.xml", "file_type": "json"}, "external_links": ["http://feeds2.feedburner.com/AustradeInvestorUpdates", "https://biotechdispatch.com.au/news/takeda-announces-cockpi-t-australia-2018-research-grants", "https://www.takeda.com/en-au/", "https://www.takeda.com/en-au/what-we-do/research--development/cockpi-t/", "https://www.takeda.com/"], "title": "Takeda rewards Australian medical research grants", "forum_title": "Austrade News"}, {"id": "XbqMbZ1jSMi8LC0sPfDgZ-DZNZgmzkeoIzqvDjfjzrH0vHMjDnihxGib5mxbnCct", "result_metadata": {"score": 30.917545}, "author": "Value Market Research", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Landscape", "relevance": 0.9044, "dbpedia_resource": "http://dbpedia.org/resource/Landscape"}], "categories": [{"score": 0.739289, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.70264, "label": "/science/weather"}, {"score": 0.644414, "label": "/science/weather/meteorological disaster/hurricane"}], "relations": [], "keywords": [{"text": "Sedatives Market Landscape Assessment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999562, "count": 1}, {"text": "Latest Trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.971995, "count": 1}, {"text": "Opportunities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592004, "count": 1}, {"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576157, "count": 1}]}, "crawl_date": "2018-11-29T14:40:09Z", "url": "https://www.openpr.com/news/1407698/Sedatives-Market-Landscape-Assessment-Latest-Trends-Opportunities-and-Forecast-2025.html", "host": "openpr.com", "text": "The key players in the sedatives market includes Advicenne Pharma, AstraZeneca Plc, Concert Pharmaceuticals, Inc., Drawbridge Pharmaceuticals Pty Ltd., NanoMedex Pharmaceuticals, Inc., Paion AG, Takeda Pharmaceutical, and The Medicines Company.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T14:33:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": -0.421198, "label": "negative"}, "text": "Drawbridge Pharmaceuticals Pty Ltd.", "relevance": 0.171982, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Advicenne Pharma", "relevance": 0.16203, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.504969, "label": "negative"}, "text": "NanoMedex Pharmaceuticals", "relevance": 0.159335, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.389558, "label": "negative"}, "text": "Concert Pharmaceuticals", "relevance": 0.155851, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc", "relevance": 0.155698, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.154289, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Paion AG", "relevance": 0.135351, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "The Medicines Company", "relevance": 0.104431, "type": "Company"}], "sentiment": {"document": {"score": 0.445949, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": "Press release from: Value Market Research The global Sedatives Market research report is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamic over the forecast period 2019-2025.", "object": {"text": "the current market dynamic", "keywords": [{"text": "current market"}]}, "action": {"verb": {"text": "impact", "tense": "present"}, "text": "impact", "normalized": "impact"}}, {"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.", "object": {"text": "significant strategies adopted by major players", "keywords": [{"text": "significant strategies"}, {"text": "major players"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by major players", "keywords": [{"text": "major players"}]}, "sentence": " Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.", "object": {"text": "the latest significant strategies", "keywords": [{"text": "latest significant strategies"}]}, "action": {"verb": {"text": "adopt", "tense": "past"}, "text": "adopted", "normalized": "adopt"}}, {"subject": {"text": "company profiles of key players operating in the global market", "keywords": [{"text": "company profiles"}, {"text": "key players"}, {"text": "global market"}], "entities": []}, "sentence": " Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.", "object": {"text": "detailed competitive landscape", "keywords": [{"text": "competitive landscape"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "key players", "keywords": [{"text": "key players"}]}, "sentence": " Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Advicenne Pharma, AstraZeneca Plc, Concert Pharmaceuticals, Inc., Drawbridge Pharmaceuticals Pty Ltd., NanoMedex Pharmaceuticals, Inc., Paion AG, Takeda Pharmaceutical, and The Medicines Company", "keywords": [{"text": "Drawbridge Pharmaceuticals"}, {"text": "Concert Pharmaceuticals"}, {"text": "NanoMedex Pharmaceuticals"}, {"text": "AstraZeneca Plc"}], "entities": [{"type": "Company", "text": "Advicenne Pharma"}, {"type": "Company", "text": "AstraZeneca Plc", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Concert Pharmaceuticals"}, {"type": "Company", "text": "Drawbridge Pharmaceuticals Pty Ltd."}, {"type": "Company", "text": "NanoMedex Pharmaceuticals"}, {"type": "Company", "text": "Paion AG"}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "The Medicines Company"}]}, "sentence": " The key players in the sedatives market includes Advicenne Pharma, AstraZeneca Plc, Concert Pharmaceuticals, Inc., Drawbridge Pharmaceuticals Pty Ltd., NanoMedex Pharmaceuticals, Inc., Paion AG, Takeda Pharmaceutical, and The Medicines Company.", "object": {"text": "The key players in the sedatives market", "keywords": [{"text": "sedatives market"}, {"text": "key players"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on \"Global Sedatives Market Research Report", "keywords": [{"text": "Global Sedatives Market"}, {"text": "new product launches"}, {"text": "new product developments"}, {"text": "future capacities"}]}, "sentence": " An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on \"Global Sedatives Market Research Report\" by requesting FREE Sample Copy at: www.valuemarketresearch.com/contact/sedatives-market/down...", "object": {"text": "An in-depth view of the competitive outlook", "keywords": [{"text": "in-depth view"}, {"text": "competitive outlook"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Market", "keywords": [{"text": "Market"}], "entities": []}, "sentence": " Market DynamicsChanging lifestyle and increasing demands from work accompanied by digitalization era, contributes to fewer hours of sleep.", "object": {"text": "lifestyle", "keywords": [{"text": "lifestyle"}]}, "action": {"verb": {"text": "DynamicsChanging", "tense": "present"}, "text": "DynamicsChanging", "normalized": "DynamicsChanging"}}, {"subject": {"text": "by digitalization era", "keywords": [{"text": "digitalization era"}]}, "sentence": " Market DynamicsChanging lifestyle and increasing demands from work accompanied by digitalization era, contributes to fewer hours of sleep.", "object": {"text": "Market DynamicsChanging lifestyle and increasing demands from work", "keywords": [{"text": "demands"}, {"text": "lifestyle"}, {"text": "Market"}, {"text": "work"}], "entities": []}, "action": {"verb": {"text": "accompany", "tense": "past"}, "text": "accompanied", "normalized": "accompany"}}, {"subject": {"text": "Rising development of new drugs", "keywords": [{"text": "new drugs"}, {"text": "development"}]}, "sentence": " Rising development of new drugs is projected to be one of the key trends spurring market growth.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Rising development of new drugs", "keywords": [{"text": "new drugs"}, {"text": "development"}]}, "sentence": " Rising development of new drugs is projected to be one of the key trends spurring market growth.", "object": {"text": "one of the key trends spurring market growth", "keywords": [{"text": "key trends"}, {"text": "market growth"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is projected to be", "normalized": "be project to be"}}, {"subject": {"text": "market growth", "keywords": [{"text": "market growth"}]}, "sentence": " Rising development of new drugs is projected to be one of the key trends spurring market growth.", "object": {"text": "the key trends", "keywords": [{"text": "key trends"}]}, "action": {"verb": {"text": "spur", "tense": "present"}, "text": "spurring", "normalized": "spur"}}, {"subject": {"text": "The industry", "keywords": [{"text": "industry"}]}, "sentence": " The industry is expected to gain significant traction during the forecast period owing to increasing demand for sedatives as an adjunct to analgesics.", "object": {"text": "significant traction", "keywords": [{"text": "significant traction"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "is expected to gain", "normalized": "be expect to gain"}}, {"subject": {"text": "strict healthcare regulatory bodies", "keywords": [{"text": "healthcare regulatory bodies"}]}, "sentence": " However, strict healthcare regulatory bodies may hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis.", "object": {"text": "the market growth.This detailed market study", "keywords": [{"text": "detailed market study"}], "entities": []}, "action": {"verb": {"text": "hinder", "tense": "future"}, "text": "may hinder", "normalized": "may hinder"}}, {"subject": {"text": "the market growth.This detailed market study", "keywords": [{"text": "detailed market study"}], "entities": []}, "sentence": " However, strict healthcare regulatory bodies may hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis.", "object": {"text": "centered on the data", "keywords": [{"text": "data"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market growth.This detailed market study", "keywords": [{"text": "detailed market study"}], "entities": []}, "sentence": " However, strict healthcare regulatory bodies may hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis.", "object": {"text": "on the data obtained from multiple sources", "keywords": [{"text": "multiple sources"}, {"text": "data"}]}, "action": {"verb": {"text": "center", "tense": "past"}, "text": "is centered", "normalized": "be center"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " However, strict healthcare regulatory bodies may hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis.", "object": {"text": "analyzed using numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis", "keywords": [{"text": "market attractiveness analysis"}, {"text": "value chain analysis"}, {"text": "forces analysis"}, {"text": "numerous tools"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " However, strict healthcare regulatory bodies may hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis.", "object": {"text": "numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis", "keywords": [{"text": "market attractiveness analysis"}, {"text": "value chain analysis"}, {"text": "forces analysis"}, {"text": "numerous tools"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "is analyzed using", "normalized": "be analyze use"}}, {"subject": {"text": "porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis", "keywords": [{"text": "market attractiveness analysis"}, {"text": "value chain analysis"}, {"text": "forces analysis"}, {"text": "porter"}]}, "sentence": " However, strict healthcare regulatory bodies may hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter\u2019s five forces analysis, market attractiveness analysis and value chain analysis.", "object": {"text": "numerous tools", "keywords": [{"text": "numerous tools"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "These tools", "keywords": [{"text": "tools"}]}, "sentence": " These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities.", "object": {"text": "employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities", "keywords": [{"text": "latest growth opportunities"}, {"text": "business strategists"}, {"text": "potential value"}, {"text": "insights"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "These tools", "keywords": [{"text": "tools"}]}, "sentence": " These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities.", "object": {"text": "to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities", "keywords": [{"text": "latest growth opportunities"}, {"text": "business strategists"}, {"text": "potential value"}, {"text": "insights"}], "entities": []}, "action": {"verb": {"text": "employ", "tense": "past"}, "text": "employed", "normalized": "employ"}}, {"subject": {"text": "These tools", "keywords": [{"text": "tools"}]}, "sentence": " These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities.", "object": {"text": "insights of the potential value of the market facilitating the business strategists with the latest growth opportunities", "keywords": [{"text": "latest growth opportunities"}, {"text": "business strategists"}, {"text": "potential value"}, {"text": "insights"}], "entities": []}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "are employed to gain", "normalized": "be employ to gain"}}, {"subject": {"text": "these tools", "keywords": [{"text": "tools"}]}, "sentence": " Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of sedatives.Browse Global Sedatives Market Research Report with detailed TOC at: www.valuemarketresearch.com/report/sedatives-market Market SegmentationThe broad sedatives market has been sub-grouped into type and application.", "object": {"text": "a detailed analysis of each application/product segment in the global market of sedatives.Browse Global Sedatives Market Research Report with detailed TOC at: www.valuemarketresearch.com/report/sedatives-market Market SegmentationThe broad sedatives market has been sub-grouped into type and application", "keywords": [{"text": "sedatives.Browse Global Sedatives"}, {"text": "SegmentationThe broad sedatives"}, {"text": "sedatives market"}, {"text": "Market Research Report"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "The strategists", "keywords": [{"text": "strategists"}]}, "sentence": " The strategists can gain a detailed insight and devise appropriate strategies to target specific market.", "object": {"text": "a detailed insight and devise appropriate strategies to target specific market", "keywords": [{"text": "appropriate strategies"}, {"text": "specific market"}, {"text": "insight"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "can gain", "normalized": "can gain"}}, {"subject": {"text": "The strategists", "keywords": [{"text": "strategists"}]}, "sentence": " The strategists can gain a detailed insight and devise appropriate strategies to target specific market.", "object": {"text": "appropriate strategies to target specific market", "keywords": [{"text": "appropriate strategies"}, {"text": "specific market"}]}, "action": {"verb": {"text": "devise", "tense": "present"}, "text": "devise", "normalized": "devise"}}, {"subject": {"text": "a focused approach", "keywords": [{"text": "approach"}]}, "sentence": " This detail will lead to a focused approach leading to identification of better opportunities.By Type", "object": {"text": "to identification of better opportunities.By Type", "keywords": [{"text": "identification"}, {"text": "Type"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}], "concepts": [{"text": "Marketing", "relevance": 0.965327, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Pharmacology", "relevance": 0.686746, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Market research", "relevance": 0.644607, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Marketing research", "relevance": 0.623886, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_research"}, {"text": "Strategic management", "relevance": 0.614873, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Online research community", "relevance": 0.606181, "dbpedia_resource": "http://dbpedia.org/resource/Online_research_community"}, {"text": "Pharmaceutical drug", "relevance": 0.602492, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Value", "relevance": 0.5846, "dbpedia_resource": "http://dbpedia.org/resource/Value"}], "categories": [{"score": 0.839143, "label": "/health and fitness"}, {"score": 0.818044, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.776332, "label": "/finance/financial news"}], "relations": [{"type": "affectedBy", "sentence": "An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on \"Global Sedatives Market Research Report\" by requesting FREE Sample Copy at: www.valuemarketresearch.com/contact/sedatives-market/down... Market DynamicsChanging lifestyle and increasing demands from work accompanied by digitalization era, contributes to fewer hours of sleep.", "score": 0.532268, "arguments": [{"text": "Global Sedatives Market Research Report", "location": [1060, 1099], "entities": [{"type": "Organization", "text": "Browse Global Sedatives Market Research Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisitions", "location": [868, 880], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "agentOf", "sentence": "An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on \"Global Sedatives Market Research Report\" by requesting FREE Sample Copy at: www.valuemarketresearch.com/contact/sedatives-market/down... Market DynamicsChanging lifestyle and increasing demands from work accompanied by digitalization era, contributes to fewer hours of sleep.", "score": 0.888471, "arguments": [{"text": "FREE Sample Copy", "location": [1115, 1131], "entities": [{"type": "Person", "text": "FREE Sample Copy"}]}, {"text": "requesting", "location": [1104, 1114], "entities": [{"type": "EventCommunication", "text": "requesting"}]}]}], "keywords": [{"text": "Value Market Research", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.871562, "count": 1}, {"text": "global Sedatives Market research report", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.802917, "count": 2}, {"text": "detailed competitive landscape", "sentiment": {"score": 0.94285, "label": "positive"}, "relevance": 0.643726, "count": 1}, {"text": "market size", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.627468, "count": 1}, {"text": "various market framework", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.623374, "count": 1}, {"text": "numerous tools", "sentiment": {"score": 0.47082, "label": "positive"}, "relevance": 0.595269, "count": 1}, {"text": "market share", "sentiment": {"score": 0.94285, "label": "positive"}, "relevance": 0.595045, "count": 1}, {"text": "global market", "sentiment": {"score": 0.94285, "label": "positive"}, "relevance": 0.591733, "count": 1}, {"text": "new product launches", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.587366, "count": 1}, {"text": "major players", "sentiment": {"score": 0.94285, "label": "positive"}, "relevance": 0.585538, "count": 1}, {"text": "detailed market study", "sentiment": {"score": 0.47082, "label": "positive"}, "relevance": 0.574988, "count": 1}, {"text": "company profiles of key players", "sentiment": {"score": 0.94285, "label": "positive"}, "relevance": 0.569629, "count": 1}, {"text": "new product developments", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.563921, "count": 1}, {"text": "sedatives market", "sentiment": {"score": 0.421776, "label": "positive"}, "relevance": 0.561723, "count": 1}, {"text": "Press release", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.557898, "count": 1}, {"text": "current market", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.554045, "count": 1}, {"text": "depth view of the competitive outlook", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.551503, "count": 1}, {"text": "regulatory bodies", "sentiment": {"score": 0.47082, "label": "positive"}, "relevance": 0.547801, "count": 1}, {"text": "growth path", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.543312, "count": 1}, {"text": "strict healthcare", "sentiment": {"score": 0.47082, "label": "positive"}, "relevance": 0.538881, "count": 1}, {"text": "latest significant strategies", "sentiment": {"score": 0.94285, "label": "positive"}, "relevance": 0.537411, "count": 1}, {"text": "Concert Pharmaceuticals", "sentiment": {"score": 0.421776, "label": "positive"}, "relevance": 0.535239, "count": 1}, {"text": "growth of the global sedative market", "sentiment": {"score": -0.647762, "label": "negative"}, "relevance": 0.526964, "count": 1}, {"text": "insights of the potential value of the market", "sentiment": {"score": 0.911974, "label": "positive"}, "relevance": 0.523026, "count": 1}, {"text": "report", "sentiment": {"score": 0.792152, "mixed": "1", "label": "positive"}, "relevance": 0.521298, "count": 4}, {"text": "detailed analysis of each application", "sentiment": {"score": -0.375873, "label": "negative"}, "relevance": 0.519398, "count": 1}, {"text": "energy drinks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518823, "count": 1}, {"text": "sedatives-market", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.518512, "count": 1}, {"text": "Drawbridge Pharmaceuticals Pty Ltd", "sentiment": {"score": 0.421776, "label": "positive"}, "relevance": 0.516314, "count": 1}, {"text": "sources", "sentiment": {"score": 0.47082, "label": "positive"}, "relevance": 0.515322, "count": 1}, {"text": "industry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514736, "count": 1}, {"text": "business strategists", "sentiment": {"score": 0.911974, "label": "positive"}, "relevance": 0.514717, "count": 1}, {"text": "tools", "sentiment": {"score": 0.651934, "mixed": "1", "label": "positive"}, "relevance": 0.513599, "count": 2}, {"text": "data", "sentiment": {"score": 0.47082, "label": "positive"}, "relevance": 0.513402, "count": 1}, {"text": "forces analysis", "sentiment": {"score": 0.47082, "label": "positive"}, "relevance": 0.512858, "count": 1}, {"text": "future capacities", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.511522, "count": 1}, {"text": "information", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.510687, "count": 2}, {"text": "developments", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.509329, "count": 1}, {"text": "Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509233, "count": 1}, {"text": "com", "sentiment": {"score": 0.336812, "mixed": "1", "label": "positive"}, "relevance": 0.508957, "count": 2}, {"text": "value", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.508729, "count": 1}, {"text": "acquisitions", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.50864, "count": 1}, {"text": "trends", "sentiment": {"score": 0.729712, "label": "positive"}, "relevance": 0.508502, "count": 1}, {"text": "financial overview", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.508309, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508117, "count": 1}, {"text": "partnerships", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.50804, "count": 1}, {"text": "collaborations", "sentiment": {"score": 0.446178, "label": "positive"}, "relevance": 0.507986, "count": 1}, {"text": "key players", "sentiment": {"score": 0.421776, "label": "positive"}, "relevance": 0.507933, "count": 1}, {"text": "consistency", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506472, "count": 1}, {"text": "demands", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506392, "count": 1}]}, "extracted_metadata": {"sha1": "bbef1aea765ae68ef5f125609d3709051ff7c453", "filename": "1543502409953.zip-17118671d2d928ddccabd91463750a6a.xml", "file_type": "json"}, "external_links": ["https://www.valuemarketresearch.com/report/sedatives-market", "https://www.valuemarketresearch.com/contact/sedatives-market/download-sample"], "title": "Sedatives Market Landscape Assessment: Latest Trends, Opportunities and Forecast 2025", "forum_title": "openPR.com - New Public Relations: Business, Economy, Finances, Banking & Insurance"}, {"id": "qCr9c8LcFFqMeMc9yCHWt6bWNH5xHga10UepYwCq1nqqovrUfYTebDu-AfFrzg0h", "result_metadata": {"score": 29.666334}, "author": "wn.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.707719, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.579477, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.968835, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.919812, "count": 1}]}, "crawl_date": "2018-11-29T14:35:20Z", "url": "https://article.wn.com/view/2018/11/29/Form_83_Takeda_Pharmaceutical_Company_Limited/", "host": "article.wn.com", "text": "Shaw & Co., L.P.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0.3462, "label": "positive"}, "text": "D. E. Shaw & Co.", "relevance": 0.929295, "type": "Company", "disambiguation": {"subtype": [], "name": "D. E. Shaw & Co.", "dbpedia_resource": "http://dbpedia.org/resource/D._E._Shaw_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.929295, "type": "Quantity"}], "sentiment": {"document": {"score": -0.437876, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}], "concepts": [{"text": "D. E. Shaw & Co.", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/D._E._Shaw_&_Co."}, {"text": "Disclosure", "relevance": 0.886111, "dbpedia_resource": "http://dbpedia.org/resource/Disclosure"}, {"text": "Information disclosure statement", "relevance": 0.861535, "dbpedia_resource": "http://dbpedia.org/resource/Information_disclosure_statement"}], "categories": [{"score": 0.796759, "label": "/finance/investing/brokerages"}, {"score": 0.78485, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.77831, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.889356, "count": 1}, {"text": "D. E. Shaw", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.877678, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.70403, "count": 1}, {"text": "PERSON", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.645313, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.594912, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.583692, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550513, "count": 1}, {"text": "Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538029, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.531384, "count": 1}, {"text": "Code", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.518922, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.511623, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.437876, "label": "negative"}, "relevance": 0.436079, "count": 1}, {"text": "L.P.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270267, "count": 1}]}, "extracted_metadata": {"sha1": "b9d660890357222fc7184edf4f6468aaffab3e9a", "filename": "1543502120222.zip-d3dea8e69a108ba437ce28a0d526b847.xml", "file_type": "json"}, "title": "Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "WN.com - Europe News"}, {"id": "2DEgFwJfrvGv9o0fmsgCLXDt-WoL0RUu4WhCqabMaKkxlJHeHqPwLKhqULo2vP2E", "result_metadata": {"score": 28.23045}, "author": "tanuj", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.792363, "label": "negative"}, "text": "Haemophilus Influenzae Infection", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Haemophilus influenzae  infection  1", "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus_influenzae__infection__1"}}], "sentiment": {"document": {"score": -0.378116, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Haemophilus influenzae", "relevance": 0.954089, "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus_influenzae"}, {"text": "Haemophilus", "relevance": 0.472107, "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus"}], "categories": [{"score": 0.929126, "label": "/health and fitness/disease"}, {"score": 0.802107, "label": "/health and fitness/therapy"}, {"score": 0.685116, "label": "/health and fitness/disorders/mental disorder/depression"}], "relations": [], "keywords": [{"text": "Ongoing Forecast Study", "sentiment": {"score": -0.378116, "label": "negative"}, "relevance": 0.990213, "count": 1}, {"text": "Haemophilus Influenzae Infection Treatment", "sentiment": {"score": -0.378116, "label": "negative"}, "relevance": 0.720876, "count": 1}, {"text": "Period", "sentiment": {"score": -0.378116, "label": "negative"}, "relevance": 0.542848, "count": 1}, {"text": "Key Insights", "sentiment": {"score": -0.378116, "label": "negative"}, "relevance": 0.13282, "count": 1}]}, "crawl_date": "2018-11-29T09:46:53Z", "url": "https://www.findmarketresearch.org/2018/11/ongoing-forecast-study-on-haemophilus-influenzae-infection-treatment-market-to-reveal-key-insights-assessed-for-2018-2026-period/", "host": "findmarketresearch.org", "text": "There are some companies which are in to development and commercialization of products in this field, such as Takeda Pharmaceutical Company Limited, Merck & Co., Inc etc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-28T05:54:00+05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.46683, "label": "negative"}, "text": "haemophilus influenzae infection", "relevance": 0.877529, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Haemophilus influenzae  infection  1", "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus_influenzae__infection__1"}}, {"count": 4, "sentiment": {"score": -0.648275, "label": "negative"}, "text": "COPD", "relevance": 0.361096, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}, {"count": 3, "sentiment": {"score": -0.462283, "label": "negative"}, "text": "hyperglycemia", "relevance": 0.216596, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom"], "name": "Hyperglycemia", "dbpedia_resource": "http://dbpedia.org/resource/Hyperglycemia"}}, {"count": 2, "sentiment": {"score": -0.433831, "label": "negative"}, "text": "azithromycin", "relevance": 0.211667, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cefuroxime", "relevance": 0.206967, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.709259, "label": "negative"}, "text": "respiratory tract", "relevance": 0.185447, "type": "Anatomy"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Meropenem", "relevance": 0.179744, "type": "Drug"}, {"count": 2, "sentiment": {"score": -0.554675, "label": "negative"}, "text": "North America", "relevance": 0.177361, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amoxicillin", "relevance": 0.174301, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ampicillin", "relevance": 0.172575, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.552788, "label": "negative"}, "text": "otitis media", "relevance": 0.172326, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Otitis media", "dbpedia_resource": "http://dbpedia.org/resource/Otitis_media"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.16546, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Trimox", "relevance": 0.162021, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": -0.554675, "label": "negative"}, "text": "Europe", "relevance": 0.154323, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": -0.449253, "label": "negative"}, "text": "penicillin", "relevance": 0.153902, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chloramphenicol", "relevance": 0.15126, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.373441, "label": "negative"}, "text": "APAC", "relevance": 0.150629, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.523793, "label": "negative"}, "text": "Dexamethasone", "relevance": 0.148344, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.141134, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.254057, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.139374, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "clarithromycin", "relevance": 0.133565, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "cefixime", "relevance": 0.132814, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ceftriaxone", "relevance": 0.131415, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Erythromycin", "relevance": 0.130016, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.126309, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "clavulanic acid", "relevance": 0.124637, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.124477, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "cefpodoxime", "relevance": 0.121012, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "loracarbef", "relevance": 0.120972, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.11981, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "sulfisoxazole", "relevance": 0.118711, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "25%", "relevance": 0.118711, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "50%", "relevance": 0.118711, "type": "Quantity"}], "sentiment": {"document": {"score": -0.655038, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "patients with invasive and serious H influenzae infections", "keywords": [{"text": "influenzae infections"}, {"text": "patients"}]}, "sentence": " Initially, patients with invasive and serious H influenzae infections are best treated with an intravenous third-generation cephalosporin until antibiotic sensitivities become available.", "object": {"text": "with an intravenous third-generation cephalosporin until antibiotic sensitivities become available", "keywords": [{"text": "intravenous third-generation cephalosporin"}, {"text": "antibiotic sensitivities"}]}, "action": {"verb": {"text": "treat", "tense": "past"}, "text": "treated", "normalized": "treat"}}, {"subject": {"text": "It"}, "sentence": " It is important to monitor the resistance rates (in the hospital or the region) of H influenzae to the different antibiotics to guide empiric antimicrobial choices while awaiting susceptibility results.", "object": {"text": "important to monitor the resistance rates (in the hospital or the region) of H influenzae to the different antibiotics to guide empiric antimicrobial choices while awaiting susceptibility results", "keywords": [{"text": "empiric antimicrobial choices"}, {"text": "susceptibility results"}, {"text": "different antibiotics"}, {"text": "resistance rates"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by nontypeable H. influenzae", "keywords": [{"text": "nontypeable H. influenzae"}]}, "sentence": " Many infections caused by nontypeable H. influenzae , include, otitis media in children and exacerbations in adults with COPD, which can be treated with oral antimicrobial agents.", "object": {"text": "Many infections", "keywords": [{"text": "infections"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "COPD", "keywords": [{"text": "COPD"}], "entities": [{"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "sentence": " Many infections caused by nontypeable H. influenzae , include, otitis media in children and exacerbations in adults with COPD, which can be treated with oral antimicrobial agents.", "object": {"text": "treated with oral antimicrobial agents", "keywords": [{"text": "oral antimicrobial agents"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "COPD", "keywords": [{"text": "COPD"}], "entities": [{"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "sentence": " Many infections caused by nontypeable H. influenzae , include, otitis media in children and exacerbations in adults with COPD, which can be treated with oral antimicrobial agents.", "object": {"text": "with oral antimicrobial agents", "keywords": [{"text": "oral antimicrobial agents"}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "can be treated", "normalized": "can be treat"}}, {"subject": {"text": "amoxicillin-clavulanate, fluoroquinolones, macrolides (e.g., azithromycin, clarithromycin), and various extended spectrum cephalosporins (e.g., cefixime, cefpodoxime, loracarbef, cefuroxime)", "keywords": [{"text": "various extended spectrum"}, {"text": "azithromycin"}, {"text": "clarithromycin"}, {"text": "cefuroxime"}], "entities": [{"type": "Drug", "text": "azithromycin"}, {"type": "Drug", "text": "clarithromycin"}, {"type": "Drug", "text": "cefixime"}, {"type": "Drug", "text": "cefpodoxime"}, {"type": "Drug", "text": "loracarbef"}, {"type": "Drug", "text": "Cefuroxime"}]}, "sentence": " Oral agents active against nontypeable strains include amoxicillin-clavulanate, fluoroquinolones, macrolides (e.g., azithromycin, clarithromycin), and various extended spectrum cephalosporins (e.g., cefixime, cefpodoxime, loracarbef, cefuroxime).", "object": {"text": "Oral agents active against nontypeable strains", "keywords": [{"text": "nontypeable strains"}, {"text": "Oral agents"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Nontypeable H. influenzae", "keywords": [{"text": "Nontypeable H. influenzae"}]}, "sentence": " Nontypeable H. influenzae is the most common cause of exacerbations of COPD in adults.", "object": {"text": "the most common cause of exacerbations of COPD in adults", "keywords": [{"text": "common cause"}, {"text": "COPD"}, {"text": "exacerbations"}, {"text": "adults"}], "entities": [{"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "24 million Americans", "keywords": [{"text": "Americans"}]}, "sentence": " Approximately, 24 million Americans have COPD and experience intermittent exacerbations, many caused by bacterial infection.", "object": {"text": "COPD and experience intermittent exacerbations", "keywords": [{"text": "experience intermittent exacerbations"}, {"text": "COPD"}], "entities": [{"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "24 million Americans", "keywords": [{"text": "Americans"}]}, "sentence": " Approximately, 24 million Americans have COPD and experience intermittent exacerbations, many caused by bacterial infection.", "object": {"text": "intermittent exacerbations", "keywords": [{"text": "intermittent exacerbations"}]}, "action": {"verb": {"text": "COPD", "tense": "past"}, "text": "have COPD", "normalized": "have COPD"}}, {"subject": {"text": "by bacterial infection", "keywords": [{"text": "bacterial infection"}]}, "sentence": " Approximately, 24 million Americans have COPD and experience intermittent exacerbations, many caused by bacterial infection.", "object": {"text": "many"}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "H. influenzae infections", "keywords": [{"text": "H. influenzae"}, {"text": "infections"}]}, "sentence": " Thus, H. influenzae infections are highly prevalent among adults with COPD.", "object": {"text": "highly prevalent among adults with COPD", "keywords": [{"text": "COPD"}, {"text": "adults"}], "entities": [{"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "two major drugs class", "keywords": [{"text": "major drugs"}, {"text": "class"}]}, "sentence": " There are two major drugs class which are effective in haemophilus influenzae infection treatment namely, antibiotics and glucocorticoids.", "object": {"text": "effective in haemophilus", "keywords": [{"text": "haemophilus"}], "entities": [{"type": "HealthCondition", "text": "haemophilus influenzae infection", "disambiguation": {"subtype": [], "name": "Haemophilus influenzae  infection  1", "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus_influenzae__infection__1"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by nonencapsulated H influenzae", "keywords": [{"text": "nonencapsulated H influenzae"}]}, "sentence": " In antibiotics, penicillin are useful in management of mucosal infections caused by nonencapsulated H influenzae.", "object": {"text": "mucosal infections", "keywords": [{"text": "mucosal infections"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "up to 25%-50% of isolates produce beta-lactamase so", "keywords": [{"text": "produce beta-lactamase"}], "entities": [{"type": "Quantity", "text": "25"}, {"type": "Quantity", "text": "50"}]}, "sentence": " However, up to 25%-50% of isolates produce beta-lactamase so are resistant to this class of drugs.", "object": {"text": "resistant to this class of drugs", "keywords": [{"text": "resistant"}, {"text": "drugs"}, {"text": "class"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Meropenem or ampicillin and chloramphenicol", "keywords": [{"text": "Meropenem"}, {"text": "chloramphenicol"}], "entities": [{"type": "Drug", "text": "Meropenem"}, {"type": "Drug", "text": "Ampicillin"}, {"type": "Drug", "text": "Chloramphenicol"}]}, "sentence": " Meropenem or ampicillin and chloramphenicol are alternative regimens.", "object": {"text": "alternative regimens", "keywords": [{"text": "alternative regimens"}], "entities": [{"type": "Drug", "text": "Meropenem"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some of the common drugs available in the market under this drug class category", "keywords": [{"text": "drug class category"}, {"text": "common drugs"}, {"text": "market"}], "entities": []}, "sentence": " Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "object": {"text": "Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin", "keywords": [{"text": "Trimox"}, {"text": "Amoxicillin"}, {"text": "clavulanic acid"}, {"text": "Zithromax"}], "entities": [{"type": "Drug", "text": "azithromycin"}, {"type": "Drug", "text": "Ceftriaxone"}, {"type": "Drug", "text": "Cefuroxime"}, {"type": "Drug", "text": "Ampicillin"}, {"type": "Drug", "text": "Amoxicillin"}, {"type": "Location", "text": "Trimox", "disambiguation": {"subtype": ["City"]}}, {"type": "Drug", "text": "Amoxicillin"}, {"type": "Drug", "text": "clavulanic acid"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Glucocorticoids", "keywords": [{"text": "Glucocorticoids"}]}, "sentence": " Glucocorticoids is the other drug class used for the treatment of H influenza .", "object": {"text": "the other drug class", "keywords": [{"text": "drug class"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the other drug class", "keywords": [{"text": "drug class"}]}, "sentence": " Glucocorticoids is the other drug class used for the treatment of H influenza .", "object": {"text": "for the treatment of H influenza", "keywords": [{"text": "influenza"}, {"text": "treatment"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "These agents", "keywords": [{"text": "agents"}]}, "sentence": " These agents are used as adjunctive therapy in H influenza meningitis for the anti-inflammatory effects and prevention of sensorineural deafness.", "object": {"text": "as adjunctive therapy in H influenza meningitis for the anti-inflammatory effects and prevention of sensorineural deafness", "keywords": [{"text": "sensorineural deafness"}, {"text": "influenza meningitis"}, {"text": "anti-inflammatory effects"}, {"text": "adjunctive therapy"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are used", "normalized": "be use"}}, {"subject": {"text": "The common drugs available in this class for the treatment of H influenza infection", "keywords": [{"text": "influenza infection"}, {"text": "common drugs"}, {"text": "class"}, {"text": "treatment"}]}, "sentence": " The common drugs available in this class for the treatment of H influenza infection is Dexamethasone (Decadron, Baldex).", "object": {"text": "Dexamethasone", "keywords": [{"text": "Dexamethasone"}], "entities": [{"type": "Drug", "text": "Dexamethasone"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "adverse effects of this drug class", "keywords": [{"text": "adverse effects"}, {"text": "drug class"}], "entities": [{"type": "HealthCondition", "text": "hyperglycemia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom"], "name": "Hyperglycemia", "dbpedia_resource": "http://dbpedia.org/resource/Hyperglycemia"}}]}, "sentence": " However, adverse effects of this drug class are hyperglycemia, hypertension, weight loss, GI bleeding or perforation synthesis, cerebral palsy, adrenal suppression, and death.", "object": {"text": "hyperglycemia, hypertension, weight loss, GI bleeding or perforation synthesis, cerebral palsy, adrenal suppression, and death", "keywords": [{"text": "GI bleeding"}, {"text": "perforation synthesis"}, {"text": "adrenal suppression"}, {"text": "cerebral palsy"}], "entities": [{"type": "HealthCondition", "text": "hyperglycemia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom"], "name": "Hyperglycemia", "dbpedia_resource": "http://dbpedia.org/resource/Hyperglycemia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "North America and Europe", "keywords": [{"text": "North America"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " North America and Europe are together expected to dominate the global haemophilus influenzae infection treatment market due to upcoming approvals, more number of research and awareness.", "object": {"text": "the global haemophilus influenzae infection treatment market due to upcoming approvals, more number of research and awareness", "keywords": [{"text": "haemophilus influenzae infection"}], "entities": [{"type": "HealthCondition", "text": "haemophilus influenzae infection", "disambiguation": {"subtype": [], "name": "Haemophilus influenzae  infection  1", "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus_influenzae__infection__1"}}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "are together expected to dominate", "normalized": "be together expect to dominate"}}, {"subject": {"text": "APAC", "keywords": [{"text": "APAC"}], "entities": [{"type": "Company", "text": "APAC"}]}, "sentence": " However, APAC is expected to witness delayed growth due to late introduction of products in the market.", "object": {"text": "delayed growth", "keywords": [{"text": "delayed growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "witness", "normalized": "witness"}}, {"subject": {"text": "some companies", "keywords": [{"text": "companies"}]}, "sentence": " There are some companies which are in to development and commercialization of products in this field, such as Takeda Pharmaceutical Company Limited, Merck & Co., Inc etc.", "object": {"text": "in to development and commercialization of products in this field, such as Takeda Pharmaceutical Company Limited, Merck & Co., Inc etc", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "commercialization"}, {"text": "Merck"}, {"text": "development"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Cephalosporin", "relevance": 0.975074, "dbpedia_resource": "http://dbpedia.org/resource/Cephalosporin"}, {"text": "Haemophilus influenzae", "relevance": 0.947301, "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus_influenzae"}, {"text": "Beta-lactamase", "relevance": 0.814861, "dbpedia_resource": "http://dbpedia.org/resource/Beta-lactamase"}, {"text": "GlaxoSmithKline", "relevance": 0.76347, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Ampicillin", "relevance": 0.722281, "dbpedia_resource": "http://dbpedia.org/resource/Ampicillin"}, {"text": "Otitis media", "relevance": 0.7099, "dbpedia_resource": "http://dbpedia.org/resource/Otitis_media"}, {"text": "Penicillin", "relevance": 0.700057, "dbpedia_resource": "http://dbpedia.org/resource/Penicillin"}, {"text": "Beta-lactam antibiotic", "relevance": 0.631392, "dbpedia_resource": "http://dbpedia.org/resource/Beta-lactam_antibiotic"}, {"text": "Pneumonia", "relevance": 0.629707, "dbpedia_resource": "http://dbpedia.org/resource/Pneumonia"}, {"text": "Meningitis", "relevance": 0.627171, "dbpedia_resource": "http://dbpedia.org/resource/Meningitis"}, {"text": "Osteomyelitis", "relevance": 0.583459, "dbpedia_resource": "http://dbpedia.org/resource/Osteomyelitis"}, {"text": "Clavulanic acid", "relevance": 0.533422, "dbpedia_resource": "http://dbpedia.org/resource/Clavulanic_acid"}, {"text": "Bacteria", "relevance": 0.52433, "dbpedia_resource": "http://dbpedia.org/resource/Bacteria"}, {"text": "Cefuroxime", "relevance": 0.484778, "dbpedia_resource": "http://dbpedia.org/resource/Cefuroxime"}, {"text": "Amoxicillin", "relevance": 0.483779, "dbpedia_resource": "http://dbpedia.org/resource/Amoxicillin"}, {"text": "Beecham", "relevance": 0.446914, "dbpedia_resource": "http://dbpedia.org/resource/Beecham_(pharmaceutical_company)"}, {"text": "Haemophilus", "relevance": 0.437699, "dbpedia_resource": "http://dbpedia.org/resource/Haemophilus"}, {"text": "Pasteurellaceae", "relevance": 0.43092, "dbpedia_resource": "http://dbpedia.org/resource/Pasteurellaceae"}, {"text": "Lyme disease", "relevance": 0.42982, "dbpedia_resource": "http://dbpedia.org/resource/Lyme_disease"}, {"text": "Influenza", "relevance": 0.427236, "dbpedia_resource": "http://dbpedia.org/resource/Influenza"}, {"text": "World Health Organization essential medicines", "relevance": 0.422142, "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization_essential_medicines"}, {"text": "Immune system", "relevance": 0.421292, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Erythromycin", "relevance": 0.420762, "dbpedia_resource": "http://dbpedia.org/resource/Erythromycin"}, {"text": "Inflammation", "relevance": 0.415193, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Infection", "relevance": 0.404816, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Antibiotic resistance", "relevance": 0.394643, "dbpedia_resource": "http://dbpedia.org/resource/Antibiotic_resistance"}, {"text": "Virus", "relevance": 0.393197, "dbpedia_resource": "http://dbpedia.org/resource/Virus"}, {"text": "Infectious disease", "relevance": 0.381813, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Antibiotic", "relevance": 0.376323, "dbpedia_resource": "http://dbpedia.org/resource/Antibiotic"}, {"text": "Sinusitis", "relevance": 0.37285, "dbpedia_resource": "http://dbpedia.org/resource/Sinusitis"}, {"text": "Infectious mononucleosis", "relevance": 0.367277, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_mononucleosis"}, {"text": "Drug", "relevance": 0.347545, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Clostridium difficile", "relevance": 0.346921, "dbpedia_resource": "http://dbpedia.org/resource/Clostridium_difficile"}, {"text": "Disease", "relevance": 0.345714, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Hib vaccine", "relevance": 0.339747, "dbpedia_resource": "http://dbpedia.org/resource/Hib_vaccine"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.33574, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Streptococcus pneumoniae", "relevance": 0.328651, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus_pneumoniae"}, {"text": "Cephalosporin antibiotics", "relevance": 0.32864, "dbpedia_resource": "http://dbpedia.org/resource/Cephalosporin_antibiotics"}, {"text": "Macrolide", "relevance": 0.325997, "dbpedia_resource": "http://dbpedia.org/resource/Macrolide"}, {"text": "Common cold", "relevance": 0.3211, "dbpedia_resource": "http://dbpedia.org/resource/Common_cold"}], "categories": [{"score": 0.914372, "label": "/health and fitness/disease"}, {"score": 0.857223, "label": "/health and fitness/therapy"}, {"score": 0.758078, "label": "/health and fitness/disease/allergies"}], "relations": [{"type": "locatedAt", "sentence": "It is important to monitor the resistance rates (in the hospital or the region) of H influenzae to the different antibiotics to guide empiric antimicrobial choices while awaiting susceptibility results.", "score": 0.46401, "arguments": [{"text": "hospital", "location": [357, 365], "entities": [{"type": "Organization", "text": "hospital", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "region", "location": [373, 379], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}]}, {"type": "locatedAt", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.568839, "arguments": [{"text": "Chloramphenicol", "location": [2025, 2040], "entities": [{"type": "GeopoliticalEntity", "text": "Chloramphenicol"}]}, {"text": "Chloromycetin", "location": [2042, 2055], "entities": [{"type": "GeopoliticalEntity", "text": "Chloromycetin"}]}]}, {"type": "playsRoleOf", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.477397, "arguments": [{"text": "Merrem IV", "location": [2122, 2131], "entities": [{"type": "Person", "text": "Merrem IV"}]}, {"text": "Meropenem", "location": [2111, 2120], "entities": [{"type": "Person", "text": "Meropenem"}]}]}, {"type": "hasAttribute", "sentence": "The common drugs available in this class for the treatment of H influenza infection is Dexamethasone (Decadron, Baldex).", "score": 0.628635, "arguments": [{"text": "Dexamethasone", "location": [2471, 2484], "entities": [{"type": "Person", "text": "Dexamethasone"}]}, {"text": "influenza infection", "location": [2448, 2467], "entities": [{"type": "HealthCondition", "text": "influenza infection"}]}]}, {"type": "hasAttribute", "sentence": "The global market for Haemophilus Influenzae Infection Treatment on basis of treatment and geography:Segmentation by Treatment;Antibiotics,Glucocorticoids On the basis of regional presence, global haemophilus influenzae infection treatment into five key regions viz.", "score": 0.611338, "arguments": [{"text": "Glucocorticoids", "location": [2909, 2924], "entities": [{"type": "Person", "text": "Glucocorticoids"}]}, {"text": "infection", "location": [2990, 2999], "entities": [{"type": "HealthCondition", "text": "infection"}]}]}, {"type": "locatedAt", "sentence": "North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "score": 0.70307, "arguments": [{"text": "Asia", "location": [3075, 3079], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3080, 3087], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "There are some companies which are in to development and commercialization of products in this field, such as Takeda Pharmaceutical Company Limited, Merck & Co., Inc etc. Request Sample Report@ https://www.persistencemarketresearch.com/samples/23044", "score": 0.337849, "arguments": [{"text": "which", "location": [3430, 3435], "entities": [{"type": "Organization", "text": "which"}]}, {"text": "companies", "location": [3420, 3429], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "There are some companies which are in to development and commercialization of products in this field, such as Takeda Pharmaceutical Company Limited, Merck & Co., Inc etc. Request Sample Report@ https://www.persistencemarketresearch.com/samples/23044", "score": 0.479971, "arguments": [{"text": "Inc", "location": [3567, 3570], "entities": [{"type": "Organization", "text": "Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://www.persistencemarketresearch.com/samples/", "location": [3599, 3649], "entities": [{"type": "Web", "text": "https://www.persistencemarketresearch.com/samples/"}]}]}, {"type": "employedBy", "sentence": "Many infections caused by nontypeable H. influenzae , include, otitis media in children and exacerbations in adults with COPD, which can be treated with oral antimicrobial agents.", "score": 0.442241, "arguments": [{"text": "adults", "location": [613, 619], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "COPD", "location": [625, 629], "entities": [{"type": "Organization", "text": "COPD"}]}]}, {"type": "employedBy", "sentence": "Thus, H. influenzae infections are highly prevalent among adults with COPD.", "score": 0.439871, "arguments": [{"text": "adults", "location": [1201, 1207], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "COPD", "location": [1213, 1217], "entities": [{"type": "Organization", "text": "COPD"}]}]}, {"type": "employedBy", "sentence": "Many infections caused by nontypeable H. influenzae , include, otitis media in children and exacerbations in adults with COPD, which can be treated with oral antimicrobial agents.", "score": 0.358204, "arguments": [{"text": "agents", "location": [676, 682], "entities": [{"type": "Person", "text": "agents"}]}, {"text": "which", "location": [631, 636], "entities": [{"type": "Organization", "text": "COPD"}]}]}, {"type": "residesIn", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.485922, "arguments": [{"text": "Ceftriaxone", "location": [1832, 1843], "entities": [{"type": "Person", "text": "Ceftriaxone"}]}, {"text": "Cefuroxime", "location": [1856, 1866], "entities": [{"type": "GeopoliticalEntity", "text": "Cefuroxime"}]}]}, {"type": "locatedAt", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.972137, "arguments": [{"text": "Ceftin", "location": [1868, 1874], "entities": [{"type": "GeopoliticalEntity", "text": "Ceftin"}]}, {"text": "Zinacef", "location": [1876, 1883], "entities": [{"type": "GeopoliticalEntity", "text": "Zinacef"}]}]}, {"type": "locatedAt", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.938814, "arguments": [{"text": "Marcillin", "location": [1898, 1907], "entities": [{"type": "GeopoliticalEntity", "text": "Marcillin"}]}, {"text": "Omnipen", "location": [1909, 1916], "entities": [{"type": "GeopoliticalEntity", "text": "Omnipen"}]}]}, {"type": "locatedAt", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.786465, "arguments": [{"text": "Omnipen", "location": [1909, 1916], "entities": [{"type": "GeopoliticalEntity", "text": "Omnipen"}]}, {"text": "Polycillin", "location": [1918, 1928], "entities": [{"type": "GeopoliticalEntity", "text": "Polycillin"}]}]}, {"type": "locatedAt", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.924448, "arguments": [{"text": "Polycillin", "location": [1918, 1928], "entities": [{"type": "GeopoliticalEntity", "text": "Polycillin"}]}, {"text": "Principen", "location": [1930, 1939], "entities": [{"type": "GeopoliticalEntity", "text": "Principen"}]}]}, {"type": "playsRoleOf", "sentence": "Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).", "score": 0.420499, "arguments": [{"text": "Trimox", "location": [1955, 1961], "entities": [{"type": "Person", "text": "Trimox"}]}, {"text": "Amoxicillin", "location": [1942, 1953], "entities": [{"type": "Person", "text": "Amoxicillin"}]}]}], "keywords": [{"text": "Haemophilus influenzae", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759176, "count": 1}, {"text": "serious H influenzae infections", "sentiment": {"score": -0.758478, "label": "negative"}, "relevance": 0.71201, "count": 1}, {"text": "North America", "sentiment": {"score": -0.799599, "label": "negative"}, "relevance": 0.658929, "count": 2}, {"text": "major drugs class", "sentiment": {"score": 0.71794, "label": "positive"}, "relevance": 0.65473, "count": 1}, {"text": "haemophilus influenzae infection treatment", "sentiment": {"score": 0.71794, "label": "positive"}, "relevance": 0.630409, "count": 2}, {"text": "nontypeable H. influenzae", "sentiment": {"score": -0.944371, "label": "negative"}, "relevance": 0.621511, "count": 2}, {"text": "common cause of exacerbations of COPD", "sentiment": {"score": -0.801974, "label": "negative"}, "relevance": 0.592734, "count": 1}, {"text": "global market", "sentiment": {"score": -0.607133, "label": "negative"}, "relevance": 0.585622, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569269, "count": 1}, {"text": "antibiotic sensitivities", "sentiment": {"score": -0.758478, "label": "negative"}, "relevance": 0.568855, "count": 1}, {"text": "bacterial infection", "sentiment": {"score": -0.859847, "label": "negative"}, "relevance": 0.567707, "count": 1}, {"text": "basis of treatment", "sentiment": {"score": -0.607133, "label": "negative"}, "relevance": 0.566247, "count": 1}, {"text": "H influenzae", "sentiment": {"score": -0.480925, "mixed": "1", "label": "negative"}, "relevance": 0.564711, "count": 2}, {"text": "class of drugs", "sentiment": {"score": 0.888504, "label": "positive"}, "relevance": 0.561212, "count": 1}, {"text": "amoxicillin-clavulanate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560827, "count": 1}, {"text": "antimicrobial agents", "sentiment": {"score": -0.944371, "label": "negative"}, "relevance": 0.55191, "count": 1}, {"text": "treatment of H influenza", "sentiment": {"score": -0.696659, "label": "negative"}, "relevance": 0.550158, "count": 1}, {"text": "clavulanic acid", "sentiment": {"score": -0.770577, "label": "negative"}, "relevance": 0.546464, "count": 1}, {"text": "basis of regional presence", "sentiment": {"score": -0.607133, "label": "negative"}, "relevance": 0.540626, "count": 1}, {"text": "otitis media", "sentiment": {"score": -0.944371, "label": "negative"}, "relevance": 0.540111, "count": 1}, {"text": "H. influenzae infections", "sentiment": {"score": -0.826961, "label": "negative"}, "relevance": 0.538163, "count": 1}, {"text": "weight loss", "sentiment": {"score": -0.932253, "label": "negative"}, "relevance": 0.537964, "count": 1}, {"text": "intravenous third-generation cephalosporin", "sentiment": {"score": -0.758478, "label": "negative"}, "relevance": 0.536623, "count": 1}, {"text": "adjunctive therapy", "sentiment": {"score": -0.696659, "label": "negative"}, "relevance": 0.535078, "count": 1}, {"text": "nontypeable strains", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533383, "count": 1}, {"text": "drug class category", "sentiment": {"score": -0.770577, "label": "negative"}, "relevance": 0.532461, "count": 1}, {"text": "global haemophilus influenzae infection treatment", "sentiment": {"score": -0.607133, "label": "negative"}, "relevance": 0.528116, "count": 1}, {"text": "common drugs", "sentiment": {"score": -0.770577, "label": "negative"}, "relevance": 0.527553, "count": 2}, {"text": "adverse effects of this drug class", "sentiment": {"score": -0.932253, "label": "negative"}, "relevance": 0.526672, "count": 1}, {"text": "Oral agents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525112, "count": 1}, {"text": "treatment of H influenza infection", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523723, "count": 1}, {"text": "anti-inflammatory effects", "sentiment": {"score": -0.696659, "label": "negative"}, "relevance": 0.523666, "count": 1}, {"text": "different antibiotics", "sentiment": {"score": 0.542092, "label": "positive"}, "relevance": 0.522789, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": -0.799599, "label": "negative"}, "relevance": 0.521696, "count": 1}, {"text": "cerebral palsy", "sentiment": {"score": -0.932253, "label": "negative"}, "relevance": 0.521696, "count": 1}, {"text": "infections", "sentiment": {"score": -0.944371, "label": "negative"}, "relevance": 0.5201, "count": 1}, {"text": "COPD", "sentiment": {"score": -0.628782, "mixed": "1", "label": "negative"}, "relevance": 0.517995, "count": 3}, {"text": "market", "sentiment": {"score": -0.770577, "label": "negative"}, "relevance": 0.51716, "count": 2}, {"text": "produce beta-lactamase", "sentiment": {"score": -0.838909, "label": "negative"}, "relevance": 0.516626, "count": 1}, {"text": "management of mucosal infections", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514883, "count": 1}, {"text": "Middle East", "sentiment": {"score": -0.799599, "label": "negative"}, "relevance": 0.514763, "count": 1}, {"text": "H influenzae infections", "sentiment": {"score": 0.888504, "label": "positive"}, "relevance": 0.513729, "count": 1}, {"text": "late introduction of products", "sentiment": {"score": -0.764421, "label": "negative"}, "relevance": 0.513601, "count": 1}, {"text": "spectrum cephalosporins", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513453, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512444, "count": 1}, {"text": "Americans", "sentiment": {"score": -0.890172, "label": "negative"}, "relevance": 0.512434, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.799599, "label": "negative"}, "relevance": 0.511481, "count": 2}, {"text": "patients", "sentiment": {"score": -0.758478, "label": "negative"}, "relevance": 0.511385, "count": 1}, {"text": "glucocorticoids", "sentiment": {"score": 0.71794, "label": "positive"}, "relevance": 0.510911, "count": 3}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510258, "count": 1}]}, "extracted_metadata": {"sha1": "3f976a987836e7aa07cbd23b506803a8faf4009a", "filename": "1543484813239.zip-ac28e8ea7cdf29338cd9c20b6ffa8bf4.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/haemophilus-influenzae-infection-treatment-market.asp", "https://www.persistencemarketresearch.com/samples/23044"], "title": "Ongoing Forecast Study on Haemophilus Influenzae Infection Treatment to Reveal Key Insights Assessed for 2018-2026 Period", "forum_title": "Research Insights | Find Market Research - Part 121"}]}